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ABSTRACT

Mechanisms of Deadenylation Regulation Under Different Cellular Conditions
By
Xiaokan Zhang

Adviser: Professor Frida Esther Kleiman

Control of gene expression by regulating mRNA stability after DNA damage has
the potential to contribute to the cells rapid response to stress. The main focus of this
dissertation is to elucidate the role(s) of nuclear PARN deadenylase in controlling mRNA
stability, hence gene expression, of factors in the p53 signaling pathway during the DNA
damage response (DDR). Understanding the mechanisms of these regulatory pathways
will provide new insights on how the control of gene expression upon DNA damage
decides cellular fate, offering new opportunities for therapeutics. In Chapter II, I
presented evidence that PARN along with the cleavage factor CstF-associated tumor
suppressor BARD1 participates in the regulation of endogenous transcripts in different
cellular conditions. In Chapter III, I identified the mRNA targets of PARN in non-stress
conditions, and contributed to describing a feedback loop between p53 and PARN, in
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which PARN deadenylase keeps p53 levels low by destabilizing p53 mRNA through its
3′ untranslated region (3’UTR) in non-stress conditions, and the UV-induced increase in
p53 activates PARN, regulating gene expression during DDR in a transactivationindependent manner. In Chapter IV, I presented evidence that PARN deadenylase has a
specific effect on the steady-state levels of not only AU-rich element-containing but also
microRNA (miRNA)-regulated nuclear mRNAs. I showed that the functional interaction
of PARN with miRNA-induced silencing complex contributes to p53 mRNA stability
regulation. These studies provide the first description of PARN deadenylase function in
miRNA-dependent control of mRNA decay and of miRNA-function in the nucleus.
Finally, in Chapter V, I determine that nucleolin is one of the RNA binding proteins that
recruits PARN to the p53 mRNA and this can be regulated by phosphorylation,
representing a novel regulatory mechanism for p53 gene expression. The data presented
in this dissertation has contributed to describe and comprehend some novel mechanisms
behind the regulation of gene expression during DDR.
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SIGNIFICANCE
Cells are constantly exposed to stress caused by environmental factors such as
oxidation, hydrolysis, alkylation, radiation and toxic chemicals. As a consequence, each
cell in our body experiences more than 74,000 damages per day. If the damage is not
repaired, DNA mutations might occur and proteins harmful to the cell might be
expressed. The regulation of gene expression during the DNA damage response (DDR) is
a fundamental cellular process that is controlled at multiple levels, such as transcription,
mRNA processing and translation. While the study of gene expression regulation during
DDR has been traditionally focused at the transcriptional level, it has recently become
apparent that the role of post-transcriptional control may be equally important.
The dynamic nature of the mRNA 3’-end processing machinery allows the
regulation of the steady-state levels of different mRNAs and has the potential to
contribute to the cells rapid response to stress. The DDR involves changes in mRNA
steady-state levels and, consequently, in gene expression of different genes. For example,
while the steady-state levels of genes involved in cell cycle and DNA repair change at
different points of the response to allow DNA repair, the steady-state levels of most
housekeeping genes are transiently decreased to avoid the formation of erroneously
processed truncated mRNAs that might generate harmful proteins.
mRNA polyadenylation and deadenylation are important processes that allow
rapid regulation of gene expression in response to different cellular conditions. As the
mRNA poly(A) tail is important in the regulation of mRNA steady-state levels,
determination of how the poly(A) tail length of a particular mRNA and, consequently, its
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stability are determined and regulated constitutes a major challenge in understanding
control of gene expression in different cellular conditions. It has been established that
modulation

of

the

length

of

poly(A)

tail

of

an

mRNA

by

the

polyadenylation/deadenylation machinery is a widespread strategy used to control mRNA
stability and protein production in different cellular conditions such as development,
mRNA surveillance, inflammatory response, cell differentiation, cancer, and especially
during the DDR. One of the mechanisms underlying the transient decrease of cellular
poly(A)+ mRNA levels after DNA damage involves the formation of a complex between
the cleavage stimulation factor CstF, the deadenylation factor poly(A)-specific
ribonuclease (PARN), and the tumor suppressors BARD1 (BRCA1-associated RING
domain 1), BRCA1 and p53. The formation of BARD1/CstF1/PARN complex has a role
in activating the deadenylase activity of PARN, while at the same time it inhibits the 3’
cleavage step of the polyadenylation reaction. PARN along with the CstF/BARD1
complex participates in the regulation of the steady-state levels of endogenous transcripts
under different cellular conditions. Any mutations or functional defects in those
polyadenylation/deadenylation factors are prone to result in deregulation of proper gene
expression, which may cause cancer.
mRNA steady-state levels are regulated by microRNAs (miRNAs), AU-rich
elements (ARE)-binding proteins (BP), polyadenylation/deadenylation factors, and RNABP that recognize cis-acting sequences in the target mRNA. The dynamic change of these
RNA-protein complexes regulates deadenylation signaling different checkpoints during
DDR. The relevance of the functional connection between these cis-acting elements and
the 3’ processing machinery is highlighted by changes in the length of the 3’UTR of
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different mRNAs in cancer cells and during cell differentiation by the use of alternative
3’ cleavage and polyadenylation signals (APA). Changes in the length of 3′UTRs of
mRNAs can eliminate or include several cis-acting elements, such as miRNA target sites
and AREs, and these changes can affect the stability, hence the abundance, of different
transcript isoforms in different subtypes of tumors. The cis-acting elements are frequently
present in genes that encode proteins involved in cell growth regulation, cell
differentiation and DDR. Increasing evidence has been presented to show the important
roles that ARE- and miRNA-mediated deadenylation plays in different biological
processes. Interestingly, a functional overlapping in the regulation of mRNA stability by
ARE- and miRNA-mediated regulatory pathways has also been described. The role of
PARN deadenylase in these regulatory processes has not been elucidated.
PARN has been shown to be involved in ARE-mediated deadenylation, and
PARN expression has an effect on the steady-state levels of ARE-containing mRNAs,
such as c-fos and c-myc, in non-stressed and UV-treated cells. In this thesis, I am
investigating the role of cis-acting signals and trans-acting factors in regulating the
stability of PARN target mRNAs. The working model in this dissertation is that PARN
deadenylase plays a role in nuclear mRNA degradation of one of its targets, the p53
mRNA, through both ARE-mediated and miRNA-mediated regulatory pathways, and that
miRNA-loaded miRISC contributes to the specific recruitment of nuclear PARN to its
target mRNA in mammalian cells. In that scenario, I also investigated the role of
nucleolin as one of the ARE-BPs involved in the recruitment of PARN deadenylase to its
target mRNAs. The studies presented in this dissertation are highly significant at several
levels. First, my studies were aimed at understanding control of gene expression by

ix

regulation of mRNA stability during DDR, a field that remains largely unexplored.
Second, my preliminary data provided first insights about the underlying molecular ties
for such regulation. I identified that nucleolin, an RB protein that is highly expressed in
cancers, interacts with PARN, an mRNA decay enzyme. Third, PARN has been
extensively studied at the biochemical level but very little is known about its biological
targets under different cellular conditions. Finally, I explored new regulatory mechanisms
in the p53 pathway. While most of the studies on the expression of genes involved in
stress response pathways have traditionally focused on transcription as a major regulator,
it has recently become apparent that the posttranscriptional control of mRNA steady-state
levels may play an equally important role. The mechanism(s) behind the regulation of
p53 mRNA levels under non-stressed as well as DNA-damaging conditions has(ve) not
been well characterized. My results indicate that PARN deadenylase keeps p53 levels
low in non-stress conditions by interacting with both AREs and miRNA targeting sites in
the 3’UTR and destabilizing the p53 mRNA. Importantly, these studies support the
functional overlap between ARE- and miRNA-mediated mRNA turnover pathways,
increasing the complexity of the signaling present in the 3’UTR of different genes. This
is consistent with the idea that cell-specific 3′ processing profiles, and hence gene
expression patterns, depends on the complexity of the signaling in the 3’UTR of the
genes and the functional/dynamic interaction of the 3′ processing machinery and the
DNA damage response/tumor suppression factors, providing functional connection
between mRNA processing and cancer subtypes. The studies presented in this
dissertation will serve as a valuable framework both for understanding these critical
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biological processes and for developing appropriate therapeutic approaches to a variety of
disorders, including cancer.
Finally, evidence is presented in this dissertation of a novel regulatory miRNAmediated pathway in the nucleus. While most studies traditionally have focused on
cytoplasmic miRNA-mediated pathways, miRNA’s nuclear functions have begun to
emerge in recent years. Although miRNA-mediated gene silencing in the nucleus has
been described, the mechanism(s) and deadenylase(s) involved in this process have not
been elucidated. The data presented here is the first to address the mechanism behind
miRNA-dependent control of deadenylation in the nucleus, showing the functional
interplay among PARN deadenylase, the AREs in the 3’UTR, miRNA abundance and
Ago-2 cellular localization. Together the studies presented here provide new insights of a
regulatory pathway that involves a novel nuclear function of miRISC in mammalian cells
as well as of the p53 pathway.
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CHAPTER I
BACKGROUND

2

NUCLEAR POLYADENYLATION/DEADENYLATION MACHINERIES
Modulation

of

the

length

of

poly(A)

tail

of

an

mRNA

by

the

polyadenylation/deadenylation machinery is a widespread strategy used to control mRNA
stability and gene expression in different cellular conditions, such as development,
mRNA surveillance, inflammatory response, cell differentiation, cancer, and the DNA
damage response (DDR). The dynamic nature of the mRNA 3’-end processing machinery
allows the regulation of the steady-state levels of different mRNAs and has the potential
to contribute to the cells rapid response to stress. Almost all eukaryotic mRNA precursors
undergo a co-transcriptional cleavage followed by polyadenylation at the 3' end. After the
signals are selected, polyadenylation occurs to full extent, suggesting that this first round
of polyadenylation is a default modification for most mRNAs. However, the length of
these poly(A) tails changes by the activation of deadenylation, which might regulate gene
expression by affecting mRNA stability, mRNA transport or translation initiation . The
mechanisms behind deadenylation activation are highly regulated and associated with
different cellular conditions. After deadenylation, depending on the cellular response,
some mRNAs might undergo an extension of the poly(A) tail or degradation. The
polyadenylation/deadenylation machinery itself, microRNAs (miRNAs) or RNA binding
factors are involved in the regulation of polyadenylation/deadenylation. Studies on the
interplay between polyadenylation and deadenylation are providing critical information
required for a mechanistic understanding of several diseases, including cancer
development.
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Figure 1. Schematic representation of the mammalian mRNA 3’ end
formation. The cleavage step of the 3’ end processing is initialed by the assembly
of cleavage complex through a cooperative binding of CstF at the G/U- and Urich region and CPSF at the AAUAAA signal. CPSF-160 directly interacts with
CstF3 (77kD) and PAP. CF I, CF II and RNAP II also play a role in the cleavage
reaction. After the cleavage step, CPSF and PAP remain bound to the cleaved
RNA and elongate a 200-adenosine residue poly(A) tail to the 3’end of the
cleaved product in the presence of PABP. Taken from Zhao et al. (1999)
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Almost all eukaryotic mRNA precursors, with the exception of histones, undergo
a co-transcriptional modification at the 3' end. The 3’ end formation includes a two-step
reaction, an initial cleavage step followed by the synthesis of a 200-adenosine residue tail
to the 3’ end of the upstream cleavage product (Figure 1; reviewed in (Zhao et al., 1999)
(Shatkin and Manley, 2000; Shi et al., 2009). In mammalian cells, the poly(A) tail length
is approximately 200-250 nucleotides long (Brawerman, 1981; Wahle and Winkler,
2013). Polyadenylation plays a fundamental role in regulating mRNA stability,
translation and nuclear export, and thus is essential for the proper control of mRNA
levels and of gene expression in eukaryotes (Colgan and Manley, 1997; Zhao et al.,
1999). It has been shown that regulation of 3’ end formation plays crucial role in cell
growth control (Chuvpilo et al., 1999; D'Ambrogio et al., 2013; Takagaki and Manley,
1998; Takagaki et al., 1996) and perhaps in diseases, especially in tumor cells (Scorilas,
2002). One of the first steps of the reaction is the recognition of the highly conserved
hexamer AAUAAA located at 10 to 30 nucleotides upstream of the cleavage site by the
cleavage and polyadenylation specific factor (CPSF) and of the G/U- and U-rich region
located further downstream by cleavage stimulation factor (CstF(Takagaki and Manley,
1997). While a relatively simple signal sequence in the precursor mRNA is required for
the reaction, many diverse and specific interactions between a large number of protein
factors are involved in the formation of polyadenylation complex and regulation of 3’ end
processing in different tissues and in different cellular conditions. While CPSF, CstF,
cleavage factors 1 and 2 (CF I and CF II, respectively), RNA polymerase II (RNAP II)
and poly(A) polymerase (PAP) play a role in the endonucleolytic cleavage step and help
to specify the site of processing; CPSF, PAP, symplekin and poly(A) binding protein
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(PABP) are involved in the polyadenylation step. CstF is one of the essential
polyadenylation factors. CstF is active most likely as a dimer with each subunit
consisting of three protein factors called CstF1 (55 kDa), CstF2 (64 kDa) and CstF3 (77
kDa). CstF2 is largely responsible for RNA binding (Takagaki and Manley, 1997). Both
CstF1 and CstF3 subunits interact with the C-terminal domain (CTD) of the largest
subunit RNAP II LS, likely facilitating the RNAP II- mediated activation of 3’-end
processing and linking transcription and RNA processing (Hirose and Manley, 1998;
McCracken et al., 1997; Mirkin et al., 2008). CstF1 plays important roles in regulation of
mRNA processing by interacting with other factors (Figure 2). It contains seven WD-40
(tryptophan-aspartic acid) repeats, which are characteristic of regulatory proteins
involved in protein-protein interactions (Neer et al., 1994; Takagaki and Manley, 1992),
and an N-terminal hydrophobic region.
All organisms are constantly exposed to a variety of environment agents that
damage the DNA, such as UV-light, ionizing radiation and chemicals, which may lead to

CstF-50 (CstF-1)

hydrophobic

WD1

WD2

WD3

WD4

WD5

WD6

1

431
14-35

106-145

171-210

215-254

260-301

303-343

395-430

Figure 2. The 3’ processing factor CstF1. The CstF1 subunit of the CstF
complex contains seven WD-40 (tryptophan-aspartic acid) repeats and an Nterminal hydrophobic region.
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replication and transcription blockages, mutagenesis, and cellular cytotoxicity (Friedberg,
1995; Wood, 1996). The maintenance of genome integrity and fidelity is essential for the
proper function and survival of all cells, and requires the coordinated control of gene
expression and DNA repair mechanisms to recognize and correct DNA lesions (Lindahl,
1993; Sancar, 1994). One example is provided by the transient decrease of cellular
poly(A)+ mRNA levels following UV-irradiation and its normal recovery as part of the
DDR (Hanawalt, 1994; Ljungman, 1999). Although the mechanism involved in this
response is still not clear, it has been suggested that the decrease of mRNA level is due to
UV-induced transcription inhibition (Donahue et al., 1996). This indeed is likely a
significant part of the mechanism. However, those studies have not considered the
important role of RNA processing on mRNA levels. Consistent with this, following UVirradiation, the 3’ cleavage step of the polyadenylation reaction is repressed as a result of
the direct interaction between the polyadenylation factor CstF1 with the tumor suppressor
factor BARD1 (Kleiman and Manley, 1999). The UV-induced inhibition of mRNA 3’
processing occurs in a similar time frame that the UV-induced decrease of poly(A)+
mRNA levels. BARD1 is a 97 kDa nuclear protein that associates with the breast cancer
susceptibility gene product BRCA1 (Wu et al., 1996). Both proteins share structural
features, they possess N-terminal RING finger motifs, which are responsible for the
BRCA1/BARD1 interaction, three ankyrin repeats that are involved in protein-protein
interactions, and two BRCA1 C-terminal (BRCT) domains that are involved in DNA
repair and cell cycle regulation. BRCA1/BARD1 stabilizes each other and their
association enhances their functions (Baer and Ludwig, 2002). It has been shown that the
DNA-damage induced inhibition of polyadenylation correlates with increasing amount of
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a BRCA1/BARD1/CstF complex formation (Kleiman and Manley, 2001), providing a
link between transcription-coupled RNA processing and DNA repair. Moreover, mRNA
3’ end processing can also be repressed following DNA damage as a result of the
proteasome-mediated degradation of RNAP II, representing another possible redundant,
mechanism to explain the UV-induced inhibition of 3’ processing (Kleiman et al., 2005).
Interestingly, the mechanism underlying the regulation of 3’ end cleavage in
response to DNA damage also involves the functional interaction of the deadenylation/
polyadenylation machineries. As discussed in Chapter II, my studies have shown that
following UV-induced DNA damage, the polyadenylation factor CstF1 directly interacts
with the deadenylation factor poly(A)-specific ribonuclease (PARN) inhibiting the 3’
cleavage step of polyadenylation and activating deadenylation in the nucleus, suggesting
the existence of alternative mechanisms to regulate gene expression under different
cellular conditions (Cevher et al., 2010). Although most of the polyadenylation factors
have been described and the reaction is now relatively well understood, the mechanisms
underlying poly(A) removal are much less defined. In mammalian cells, the removal of
the mRNA poly(A) tail is the earliest and rate-limiting step in mRNA decay (Chen and
Shyu, 2003; Wilusz et al., 2001). Several mRNA decay pathways have been studied in
eukaryotic cell, most of which are deadenylation dependent (Parker and Song, 2004).
Two major PARN-mediated pathways of mRNA degradation have been defined: the 3’5’ decay pathway and the deadenylation-dependent decapping pathway (Figure 3;
(Beelman and Parker, 1995; von der Haar et al., 2004). In the 3’-5’ decay pathway the
degradation occurs in the cytoplasmic exosome in the 3’-5’ direction after the removal of
the poly(A) tail, while in the deadenylation-dependent decapping pathway degradation is

8

initiated by deadenylation followed by DCP1:DCP2- mediated decapping and 5’-3’
exonucleolytic degradation of mRNA by the Xrn1p 5’ exonuclease (Caponigro and
Parker, 1996; Mukherjee et al., 2002). In addition to these general mRNA decay
pathways, other degradation pathways exist. For example, another well-known mRNA
decay pathway is nonsense mediated mRNA decay (NMD). NMD is a quality control
mechanism which

Figure 3. PARN-mediated degradation of mRNA in the cytoplasm. Two major
PARN-mediated pathways of mRNA degradation have been defined: 1) After the
removal of the poly(A) tail, mRNA is first decapped by DCP followed by
exonuclease XRN1-dependent degradation in the 5’3’ direction. 2) After
deadenylation, mRNA degradation occurs in the 3’5’ direction by the exosome
followed by decapping of the 5’ end.

Modified from Dr. Wilusz lab webpage

http://www.cvmbs.colostate.edu/mip/wiluszlab/whatwedo.html
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selectively eliminates mRNAs harboring premature termination codons (Karam et al.,
2013; Li and Wilkinson, 1998; Maquat, 1995). NMD is believed to occur not only in the
cytoplasm but also in the nucleus since some ribosomal and translational activities have
been detected in that compartment (Ishigaki et al., 2001; Trcek et al., 2013). Interestingly,
PARN copurifies with essential NMD factors and PARN down-regulation abrogated
nonsense-mediated decay (Lejeune et al., 2003).
The steady-state levels of cellular mRNAs are determined by the balance between
their biosynthesis and turnover. Different mRNAs within the same cell have distinct
lifetimes. In mammalian cells, mRNA lifetimes range from several minutes to days,
depending on various genes and the cellular conditions (Khodursky and Bernstein, 2003).
The mechanisms controlling deadenylation are dynamic and highly regulated.
Deadenylation processes are a widespread strategy that allows rapid control of mRNA
stability, and represent additional checkpoint targets in the regulation of gene expression.
Deadenylases are the key catalytic exoribonucleases that are required for proper
regulation of poly(A) tail length by degrading poly(A) tail in a 3’ to 5’ direction. In
mammalian cells, a number of deadenylases have been identified and studied in detail.
There are two superfamilies of deadenylases: DEDD (Asp-Glu-Asp-Asp)-type enzyme,
and EEP (endonuclease-exonuclease-phosphatase)-type deadenylase (Goldstrohm and
Wickens, 2008). All known deadenylases belong to either superfamilies, for example,
POP2, PARN, poly(A) nuclease (PAN2) and CAF1 deadenylase belong to DEDD
superfamily, while CCR4 and Nocturnin deadenyase belong to EEP superfamily
(Goldstrohm and Wickens, 2008; Thore et al., 2003; Zuo and Deutscher, 2001).
Interestingly, some multi-subunit deadenylases are composed from subunits from both
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families (Doidge et al., 2012). It has been shown that deadenylases localize both in the
nucleus and the cytoplasm and are involved in different cellular processes. The best
characterized deadenylases so far are the CCR4-POP2-NOT multi-subunit complex,
which is the predominant deadenylase in eukaryotes, PARN, a divalent metal-ion
dependent, processive and cap-interacting exoribonuclease, and (PAN), which is involved
in early steps of poly(A) tail metabolism.
PARN is one of the three major poly(A) specific 3’ exoribonucleases identified in
mammalian cells (Mitchell and Tollervey, 2000; Wu et al., 2005). PARN is expressed
ubiquitously in all tissues of most eukaryotic organisms (Copeland and Wormington,
2001). In calf thymus cell free extracts and in Xenopus oocytes two isoforms of PARN
have been described with molecular sizes of approximately 74 kDa and 62 kDa, both of
which have shown enzymatic activity and different nuclear-cytoplasmic distribution.
While the 74 kDa isoform of PARN is exclusively nuclear, the 62 kDa isoform is
cytoplasmic (Korner et al., 1998; Martinez et al., 2000). So far, it has remained obscure
how the subcellular localization of PARN is regulated, although it appears likely that
proteolytic cleavage plays a role. While the cytoplasmic PARN’s activity has been
extensively studied, the nuclear functions of PARN are not completely understood.
PARN is found mostly in the nucleus and it does not seem tk play a key role in
cytoplasmic mRNA decay (Ota et al., 2011). PARN has been identified as an oligomeric,
highly processive, metal-ion dependent and cap-interacting poly(A) specific 3’
exonuclease (Grishin, 1998). PARN consists of a nuclease domain that performs the
deadenylation reaction, a R3H domain, which is constituted by an invariant arginine that
is separated by three residues from a highly conserved histidine and binds single stranded
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nucleotides, and a RNA recognition motif (RRM) (Figure 4; (Wu et al., 2005). While the
R3H domain is responsible for PARN’s specificity for single-stranded poly(A) (Martinez
et al., 2001), the RRM harbors the cap binding properties (Nilsson et al., 2007). It also
has been shown that its deadenylation activity and processivity is enhanced by the mRNA
5’-end-located cap structure (Astrom et al., 1992; Dehlin et al., 2000; Korner et al., 1998;
Martinez et al., 2001). On the other hand, PARN activity is inhibited by cap binding
protein (CBP80) or nuclear poly(A) binding protein-1 (PABPN-1) (Balatsos et al., 2006;
Gao et al., 2001). It has been suggested that PARN simultaneous interaction with the cap
structure and the 3’ end located poly(A) tail shields the 5’ from decapping enzymes and
initiates the deadenylation process. Interestingly, the communication between both the 3’
and 5’ ends of mRNA is very important because it integrates the initiation of translation,
translation and mRNA turnover (Martinez et al., 2001).

Figure 4. PARN consists of a nuclease domain, a R3H domain, and a RRM
motif. R3H domain, a single-stranded nucleic-acid-binding domain, is responsible
for PARN’s specificity for single-stranded poly(A), while the RRM harbors the
cap binding properties. Modified from He et al. (2013).
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Besides, PARN can promote deadenylation of AU-rich elements (AREs)containing mRNAs in the presence of tristetraprolin (TTP; (Lai et al., 2003).
Interestingly, it has been described that UV induces stabilization of ARE-containing
mRNAS; such as c-fos, kin17, c-jun, IB and c-myc (Blattner et al., 2000). It has also
been shown that the UV-induced transcript stabilization and enhanced protein levels of
short basal half–life, such as oncogenes, apoptosis and cell-cycle related genes, growth
factors and cytokines, is due to the inhibition of cytoplasmic mRNA deadenylation and
degradation (Gowrishankar et al., 2005).

AU RICH ELEMENT MEDIATED DEADENYLATION
About 54% of human genes have more than one conserved polyadenylation sites
that show different efficiencies of polyadenylation (Tian et al., 2005). Several cis-acting
elements within the 3’ untranslated region (3’UTRs) are responsible for the selection
among these alternative polyadenylation (APA) sites. Although a direct connection
between APA and the polyadenylation/deadenylation machinery has not been described,
the selection between the distal or proximal alternative signals might cause the inclusion
or

exclusion

of

other

cis-acting

RNA

elements

which

are

involved

in

polyadenylation/deadenylation processes (Figure 5). The relevance of these regulatory
processes is highlighted by the finding that changes in the length of the 3’ UTRs of
different mRNAs due to alternative 3’ cleavage and polyadenylation changes the number
of miRNA target sites and AREs in cancer cells (Mayr and Bartel, 2009; Shi, 2012; Singh
et al., 2009), and during cell differentiation (Ji et al., 2009; Sandberg et al., 2008;
Zlotorynski and Agami, 2008). Interestingly, deadenylation is often under the control of
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cis-acting regulatory elements, which includes AREs and miRNA target sites, within the
3’UTRs of eukaryotic mRNAs.
About 12% of mammalian mRNAs bear an important regulatory signal known as
AREs in their 3’UTRs, which has been shown to play significant roles in mRNA stability
regulation (Guhaniyogi and Brewer, 2001). The ARE typically contains one or several
AUUUA pentamer repeats within a U-rich region of the 3’UTR (Chen and Shyu, 1995;
Lagnado et al., 1994; Zubiaga et al., 1995). ARE sequences are frequently present in
genes that encode tightly regulated proteins involved in cell growth regulation, cell
differentiation and responses to external stimuli. The destabilizing functions of AREs are

Figure 5. Schematic diagrams of cis-acting RNA sequences at the 3'UTR
involved in polyadenylation/deadenylation processes. The selection between
the proximal or distal alternative polyadenylation signals leads to the exclusion or
inclusion of cis-acting RNA sequences, such as miRNA target sites and ARE,
which might mediate polyadenylation/deadenylation processes. Taken from
Zhang et al., (2010)(Zhang et al., 2010)(Zhang et al., 2010)(Zhang et al.,
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2010)(Zhang et al., 2010)(Zhang et al., 2010)(Zhang et al., 2010)(Zhang et al.,
2010)(Zhang et al., 2010)(Zhang et al., 2010)(Zhang et al., 2010)(Zhang et al.,
2010)
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important because in their absence proto-oncogenes, such as c-fos, c-myc and c-jun,
could become oncogenes (Schiavi et al., 1992).
A number of trans-acting factors, known as ARE-binding proteins (ARE-BPs),
regulate ARE-mediated decay and, subsequently, modulate the stability of AREcontaining mRNAs. ARE-BPs either recruit deadenylases to the target mRNAs
promoting deadenylation or block the recruitment of deadenylases and exosome
inhibiting deadenylation. The ARE-BPs that promote ARE-containing mRNAs decay
include tristetraprolin (TTP), butyrate response factor 1 (BRF1), AU-rich binding factor 1
(AUF1) and KH-type splicing regulatory protein (KHSRP or KSRP); only Hu protein R
(HuR) has been shown to play a role in stabilizing ARE-containing mRNAs (Barreau et
al., 2005; Fan and Steitz, 1998; Ma et al., 1996; Westmark et al., 2005). For example,
TTP directs its target ARE-containing mRNA tumor necrosis factor (TNF-α) for
degradation by expediting removal of the poly(A) tail. Interestingly, the phosphorylation
of TTP inhibits the recruitment of CAF1 deadenylase, and as a result, it reduces the
ability of TTP to promote deadenylation (Dean et al., 2004; Lai et al., 1999; Marchese et
al., 2010; Winzen et al., 2004). Supporting the idea that CAF1-CCR4-NOT deadenylase
complex plays a critical role in ARE-mediated deadenylation, knockdown of CAF1 has
been shown to abrogate deadenylation and decay of the ARE-containing α-globin mRNA
(Schwede et al., 2008; Zheng et al., 2008). Interestingly, PARN deadenylase has also
been shown to be involved in ARE-mediated deadenylation: KSRP recruits PARN to
ARE-containing mRNAs to initiate the poly(A) tail shortening that precedes degradation
by the exosome (Gherzi et al., 2004). PARN could also promote TTP-directed

16

Figure 6. Model of ARE -mediated regulation of deadenylation. The ARE binding proteins mediate destabilization and/or stabilization of the ARE containing mRNAs. ARE-BPs, such as AUF1, TTP, BRF1 and KHSRP, recruit
deadenylases, such as PARN and CAF1-CCR4-NOT, to target ARE-containing
mRNAs and initiate the deadenylation process that precedes degradation. Another
ARE -BP, HuR, plays a role in stabilizing ARE -containing mRNAs by blocking
the binding of ARE-BPs involved in the destabilization of ARE -mRNAs, such as
AUF1, TTP and KHSRP. This competition stabilizes the association of PABP to
the poly(A) tail or prevents the recruitment of deadenylases to the ARE -mRNA.
Taken from Zhang et al., (2010)
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deadenylation in vitro (Korner et al., 1998; Lai et al., 2003; Lin et al., 2007; Moraes et
al., 2006). As discussed in Chapters II and III, my recent studies also indicated that
PARN deadenylase has a role regulating the stabilities of ARE-containing mRNAs, such
as c-fos and c-myc, in non-stressed cells (Cevher and Kleiman, 2010; Devany et al.,
2013).
Nucleolin is a multifunctional ARE-BP with multiple subcellular localizations in
the cell. Nucleolin is localized ubiquitously in the nucleolus, and is also found in other
nuclear regions, as well as in the cytoplasm and the plasma membrane (Borer et al., 1989;
Ginisty et al., 1999). Nucleolin protein contains multiple phosphorylation sites in its
acidic N-terminal region, four RNA-binding domains mediating the interaction with
mRNAs and pre-rRNA in the central region, and arginine/glycine-rich domain
(RGG/GAR) in the C-terminal region, which can also interact with target mRNAs as well
as with other proteins (Figure 7; Ghisolfi et al., 1992; Serin et al., 1996; Bouvet et al.,
1998; (Abdelmohsen et al., 2011; Bouvet et al., 1998; Ghisolfi et al., 1992; Serin et al.,
1996). Phosphoprotein nucleolin could be phosphorylated by numerous kinases, such as
Cdc2, casein kinase II (CKII), protein kinase C (PKC) and the stress activated protein
kinase p38 (Dranovsky et al., 2001; Tediose et al., 2010; Yang et al., 2002; Zhou et al.,
1997). The role of most of these phosphorylation events is not well understood. Nucleolin
has been implicated in many different cellular processes, such as chromatin remodeling
(Angelov et al., 2006), ribosomal RNA (rRNA) processing (Ginisty et al., 1998),
ribosome assembly (Turner et al., 2009) and nucleo-cytoplasmic transport (Hovanessian
et al., 2010). Besides, nucleolin participates extensively in the post-transcriptional fate
control of mRNA targets, which typically contain AREs in their 3’UTR.
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Nucleolin modulates the stability and translation of target mRNAs through
multiple ways. First, nucleolin affects mRNA turnover, both increasing and decreasing
mRNA half-life, by interacting with the 5’UTR and/or 3’UTR of target mRNAs. For
example, in leukemia cells, nucleolin enhances the expression of pro-oncogenic protein
B-cell lymphoma 2 (Bcl-2), which blocks apoptosis in cancer cells (Yang et al., 1997), by
stabilizing BCL2 mRNA through the association with its ARE at 3’UTR (Sengupta et al.,
2004). Another mRNA target of nucleolin is the amyloid precursor protein (APP), which
is linked to Alzheimer’s disease. Nucleolin associates with the 3’UTR of APP mRNA,
and accelerates its degradation in response to stress (Westmark and Malter, 2001).
Nucleolin also has influence on the translation of a subset of associated mRNAs.

Figure 7. Schematics of nucleolin domains: The acidic N-terminal region of
nucleolin protein contains multiple phosphorylation sites; the central region
contains four RNA-binding domains, which are responsible for the interaction with
mRNAs and pre-rRNA; and arginine/glycine-rich domain (RGG/GAR) in the Cterminal region can also interact with target mRNAs and protein factors. Taken
from Bhatt et al., (2012)
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Nucleolin has been found to bind to p53 mRNA and suppressed its translation
(Takagi et al., 2005). Interestingly, nucleolin is highly expressed in proliferating cells,
such as cancer and stem cells. Nucleolin’s ability to associate with mRNA of target
genes, which are functionally involved in stress response, cell survival, as well as cancer,
and regulate their expression through changes of either mRNA stability or translation
efficiency, might explain its implication in human disease. Recently, nucleolin has also
been reported to play a role in the regulation of the biogenesis of tumorigenic
microRNAs, such as miR-15a and miR-16 (Pickering et al., 2011), suggesting new roles
for nucleolin in controlling gene expression.

miRNA MEDIATED DEADENYLATION
miRNAs comprise a large family of small single-stranded non-coding RNAs
(~21nt in length), which are encoded within the genome of species ranging from
protozoans to plants to mammals. miRNAs play key roles in a broad range of biological
processes. In mammals, it is predicted that the regulation of more than 60% of all proteincoding genes are mediated by miRNAs. They act at the post-transcriptional level to
modulate gene expression, by imperfectly base-pairing to the target mRNAs. In most
studied animals’ miRNAs, the hybrids are formed between the miRNA 5’- proximal
“seed” region and the complementary sequences in the 3’UTRs of the target mRNA
(Bushati and Cohen, 2007; Filipowicz et al., 2008; Friedman et al., 2009; Ghildiyal and
Zamore, 2009; Mayr and Bartel, 2009). It has been shown that each mRNA could be
regulated by more than one miRNA, and each miRNA could base-pair with more than
one target mRNAs.
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While most studies traditionally have focused on cytoplasmic miRNA-mediated
pathways, miRNA’s nuclear functions have begun to emerge in recent years. Although
miRNA-mediated gene silencing in the nucleus has been described (Nishi et al., 2013;
Robb et al., 2005), the mechanism(s) and deadenylase(s) involved in this process have
not been elucidated. Generally, miRNAs inhibit protein synthesis either through
translation repression and/or through deadenylation activation, which leads to mRNA
degradation (Chekulaeva and Filipowicz, 2009; Eulalio et al., 2008; Filipowicz et al.,
2008). These two mechanisms have been identified as two distinct independent pathways:
the ability of miRNAs to expedite deadenylation does not depend on decreased
translation; nor does translational repression by miRNAs require a poly(A) tail (Wu et al.,
2006). Recently, it is also reported that some miRNAs could also function as translation
activator in specific situations (Henke et al., 2008; Orom et al., 2008; Vasudevan et al.,
2008). miRNAs function in the form of ribonucleoprotein complexes, known as miRNAinduced silencing complex (miRISC), which deliver miRNAs to their mRNA targets.
Argonaute (Ago) and GW182 family proteins are the best-characterized protein
components involved in the miRNA-mediated gene expression control (Chekulaeva and
Filipowicz, 2009; Eulalio et al., 2008).
The key components of miRISCs are Ago family proteins. Ago proteins contain
three evolutionarily conserved domains, PAZ, MID and PIWI. Through these domains,
Ago proteins are able to associate with 3’ and 5’ end of the miRNA (Jinek and Doudna,
2009; Peters and Meister, 2007). In mammals, four Ago proteins, Ago1 through Ago4,
function in miRNA induced translation repression. Interestingly, Ago proteins are able to
repress protein synthesis when artificially tethered to the mRNA 3’UTR (Pillai et al.,

21

2004; Pillai et al., 2005; Wu et al., 2008), indicating that their involvement in control of
mRNA expression is miRNA-independent. It has been shown that some Ago proteins are
more potent repressors than others and cell- and tissue-specificity has also been reported
in some studies (Wu et al., 2008). It has also been described that knockdown of Ago2 in
human HEK293 cells lead to a much more profound effect on miRNA-mediated
repression than the knockdown of the other three Ago proteins, suggesting that in
mammals Ago2 may have some specific functions that other Ago proteins cannot
complement (Schmitter et al., 2006). GW182 proteins are another group of factors crucial
for miRNA-mediated functions (Eulalio et al., 2009). There are three mammalian GW182
proteins, known as TNRC6A, -B and –C. They interact directly with Agos through their
GW repeats located in the N-terminal portion of the protein, and act downstream of Agos
(Eulalio et al., 2009; Till et al., 2007). It has been shown that the disruption of GW182Ago interaction by point mutations or peptide competition results in abrogation of
miRNA-mediated repression, indicating the crucial role of GW182-Ago interaction
(Eulalio et al., 2009; Till et al., 2007)). Additional protein components of miRISCs have
also been identified to function as regulators in miRNA-mediated repression (Peters and
Meister, 2007).
Much evidence supports the idea that miRNAs destabilize target mRNAs through
deadenylation and subsequent decay (Figure 8). Many studies have showed that the levels
of specific miRNAs, or the activity of the miRNA machinery, have profound effect on
the level of miRNA-targets and that the miRNA-mediated downregulation of the levels of
target mRNA has important biological consequences (Johnson et al., 2005; Sampson et
al., 2007; Wakiyama et al., 2007). The deadenylation and the subsequent decay of
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mRNAs targeted by miRNAs require the Ago and GW182 components of the miRISC
(Akao et al., 2006; Lazzaretti et al., 2009). The knockdown of human Ago2 abrogates
miRNA-mediated deadenylation; while the disruption of GW182-Ago interaction also
fails to activate mRNA deadenylation (Eulalio et al., 2008; Till et al., 2007). The
cytoplasmic poly(A) binding protein 1 (PABPC-1) is an additional protein component
that is critical for the miRNA-mediated deadenylation. It has been shown that a
conserved motif in GW182 interacts with the C-terminal domain of PABPC-1 and that
this interaction and the activity of PABPC-1 contribute to miRNA-mediated poly(A)
removal (Fabian et al., 2009; Jinek et al., 2010; Zekri et al., 2009). It has been proposed
that the miRNA-mediated degradation of mRNAs involves the association of Ago

Figure 8. Model of miRNA-mediated deadenylation. miRISCs, which contain
Ago, GW182, PABPC1 and either CAF1-CCR4-NOT (as indicated) or Pan2Pan3 (not shown) deadenylases, deliver miRNAs to the target mRNAs and
mediate deadenylation, which leads subsequently to mRNA degradation. Taken
from Zhang et al., (2010)
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proteins to the miRNAs and the recruitment of GW182 to the target mRNAs via its Nterminal domain; then the GW182 C-terminal silencing domain recruits the deadenylase
complex through the interaction with PABPC-1 (Goss and Kleiman, 2013). One of the
most studied deadenylases involved in miRISCs is the CAF1-CCR4-NOT1 complex,
which contains two protein factors with deadenylase activity, CCR4 and CAF1. It has
been shown that the CAF1-CCR4-NOT complex associates with PABPC-1, and the
deadenylase activity of the CAF1-CCR4-NOT complex is necessary for the miRNAmediated degradation (Zekri et al., 2009). Supporting these results, both the knockdown
of CAF1 or NOT1 expression and the over-expression of CCR4 or CAF1 mutants
significantly reduce miRNA-mediated deadenylation and mRNA decay, but not
translational repression (Behm-Ansmant et al., 2006; Fabian et al., 2009; Piao et al.,
2010). Although the miRISC has been shown to functionally interact with several
deadenylases, its functional interaction with PARN has not been elucidated.
Interestingly, some of the seed signals recognized by miRNA overlap with AREs in the
3’UTR (Bhattacharyya et al., 2006; Jing et al., 2005). Although the exact contribution of
miRNAs, miRISC, AREs and ARE-BPs to mRNA decay has not been elucidated yet,
recent studies have described a functional overlapping on mRNA stability between AREand miRNA-mediated regulatory pathways (Figure 9. It has been shown that miRNAs
can functionally interact with ARE-BPs, and factors involved in miRNA metabolism,
such as Dicer and Ago, are required for ARE-mediated decay (Jing et al., 2005). For
example, it has been shown that HuR can bind AREs present in c-Myc 3’UTR at a site
proximal to that recognized by let-7 miRNA. HuR appeared to facilitate the targeting of
let-7-loaded miRISC to an adjacent region of HuR binding site, and to mediate the
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reduction of c-Myc mRNA levels (Kim et al., 2009). Another example is the cooperation
of ARE-BP TTP and miR-16 in targeting tumor necrosis factor-α mRNA for AREmediated mRNA degradation (Jing et al., 2005). TTP does not bind directly miR-16 but it
forms a complex with miRISC, and that complex recruits the deadenylase and the
exosome for mRNA degradation. HuR can also relieve CAT-1 mRNA from miR-122
repression upon stress in human liver cells (Bhattacharyya et al., 2006).

Figure 9. Model of overlapping in the ARE - and miRNA-regulated
deadenylation. Cooperation of ARE s-BPs, miRNAs, deadenylases and exosome
is essential for the regulation of mRNA stability. The recruitment of the ARE BPs HuR or TT P to the ARE sequence assists the targeting of let-7- or miR-16loaded miRISC complexes, respectively, to the most proximal site to the ARE
sequence. Taken from Zhang et al., (2010)
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CHAPTER II
EFFECT OF PARN EXPRESSION ON ENDOGENOUS GENE
EXPRESSION UNDER DIFFERENT CELLULAR CONDITIONS
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INTRODUCTION
The steady-state levels of cellular mRNAs are determined by the balance between
their biosynthesis and turnover. The turnover rates of individual mRNAs can vary in
response to changes in the cellular environment and the mRNA poly(A) tail is one of the
key structures required for correct regulation of mRNA degradation. The poly(A) tails are
also critical for regulation of mRNA processing, translation and subcellular localization,
such as nuclear export (Colgan and Manley, 1997; Mandel et al., 2008; Zhao et al.,
1999). Thus, the poly(A) tail is a fundamental cis-acting element that is essential for
proper control of gene expression at several different levels in eukaryotes. The poly(A)
tail is synthesized in the nucleus through a two-step polyadenylation reaction; an initial
cleavage step, which specifies the 3’ end of the mRNA, followed by the synthesis of a
200 adenosine residues tail to the 3’ end of the upstream cleavage product (reviewed in
(Shatkin and Manley, 2000; Zhao et al., 1999). The polyadenylation reaction is by itself a
highly regulated event and is used for example to regulate tissue or developmental
specific gene expression and for cell growth control (Chuvpilo et al., 1999; Takagaki and
Manley, 1998; Takagaki et al., 1996). Several examples of cases are known which links
deficiencies in the polyadenylation machinery to disease development, including tumor
formation (reviewed by (Scorilas, 2002).
The polyadenylation reaction requires the assembly of a rather large number of
interacting protein factors that recognize a relatively simple set of cis-acting signal
sequence elements in the mRNA precursor. Cleavage stimulation factor (CstF) is one of
the essential polyadenylation factors. CstF is active most likely as a dimer with each
subunit consisting of three protein factors called CstF1, CstF2, and CstF3. CstF3 interacts
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directly with the down-stream located GU-rich cis-acting element. Both the CstF1 and
CstF2 subunits interact specifically with the carboxy-terminal domain (CTD) of RNA
polymerase II largest subunit (RNAP II LS), likely facilitating the RNAP II-mediated
activation of 3’ end processing (Hirose and Manley, 1998; McCracken et al., 1997).
Moreover, 3’ end processing can be repressed following DNA damage as a result of the
interaction between CstF1 and BRCA1-associated RING domain protein (BARD1,
(Kleiman and Manley, 1999) and of the proteasome-mediated degradation of RNAP II
(Kleiman et al., 2005). Studies from Dr. Kleiman’s lab have recently shown that cells
with reduced levels of CstF display decreased viability following UV treatment, reduced
ability to ubiquitinate RNAP II, and defects in repair of DNA damage (Mirkin et al.,
2008), supporting the idea that CstF plays a direct role in the DNA damage response.
Although most of the polyadenylation factors have been described and the
reaction is now relatively well understood, the mechanisms behind poly(A) removal are
much less defined. In mammalian cells, the earliest and rate limiting step in mRNA decay
is the removal of the mRNA poly(A) tail (Chen and Shyu, 2003; Wilusz et al., 2001).
PARN is one of the three major poly(A) specific 3’ exoribonuclease identified in
mammalian cells and characterized thus far (Mitchell and Tollervey, 2000; Parker and
Song, 2004; Wu et al., 2005). It is expressed ubiquitously in all tissues of most eukaryotic
organisms (Copeland and Wormington, 2001) and localizes both to the nucleus and the
cytoplasm. PARN shows high specificity for single stranded poly(A) (Korner and Wahle,
1997; Martinez et al., 2001), and its deadenylating activity is stimulated by the mRNA 5’
end located cap structure (Dehlin et al., 2000; Gao et al., 2001; Martinez et al., 2001;
Nilsson et al., 2007; Wu et al., 2009). Although the exact function of PARN in the
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nucleus is unknown, it has been established that the CBP80 (Balatsos et al., 2006) and the
poly(A) binding protein 1 (PABPN1, (Gao et al., 2001) both inhibit PARN activity.
Interestingly, the cap binding complex (CBC) has also been shown to play a role in
polyadenylation by stabilizing the RNA/CstF complex formed in the nucleus and the
depletion of CBC reduces the mRNA cleavage reaction (Flaherty et al., 1997).
Dr. Cevher and colleagues (2010) found that the polyadenylation factor CstF1
interacts strongly with the same region of PARN, the C-terminal domain, as its inhibitor
CBP80. Like the previously described CstF/BARD1/BRCA1 complex, the CstF/PARN
complex formation is stimulated upon UV light–treatment and participates in the
inhibition of the 3’ cleavage reaction of polyadenylation upon DNA-damaging
conditions. More importantly, they also showed that the CstF1/PARN interaction
activates deadenylation in vitro and that UV treatment can activate nuclear PARN
deadenylase activity. They provided evidence that the tumor suppressor BARD1 strongly
activates deadenylation by PARN in the presence of CstF1 and that the siRNA-mediated
knockdown of BARD1 decreases the UV-induced activation of deadenylation. In
addition, their data showed that CBP80 and CstF1 could compete for binding to PARN,
providing a mechanism to regulate PARN deadenylase activity in different cellular
conditions. As part of those studies, I determined that these functional interactions
correlate with changes in both stability and polyadenylation of different mRNA
precursors, such as housekeeping genes and some clinically significant genes, upon UV
treatment and that reduced expression of PARN is sufficient to revert the observed
changes. Taken together, these results indicate that the CstF/PARN complex plays a role
in the inhibition of 3’ cleavage of polyadenylation and the activation of deadenylation in
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the nucleus upon DNA-damaging conditions, suggesting the existence of alternative
mechanisms to regulate gene expression in different cellular conditions. This manuscript
was the first report describing a mechanism of gene expression regulation in response to
DNA damage that involves the deadenylation/polyadenylation machinery.
RESULTS
The data presented by Cevher and colleagues (2010) provided evidence that DNA
damage induces the activation of PARN-mediated mRNA deadenylation in the nucleus.
To further investigate this, I determined the expression levels of different endogenous
mRNAs in cells treated by UV irradiation and with siRNAs targeting PARN. Briefly, 24
h after transfection with the indicated siRNAs, cells were exposed to UV light and total
nuclear RNA was purified at different time points after UV treatment. Gene expression
was analyzed by real-time quantitative reverse transcription PCR (qRT–PCR). Random
and oligo-(dT) primers were used for the RT reaction and qPCR reactions were
performed using commercially available primers. First, the expression levels of two
-actin, were analyzed under different cellular
conditions. The qRT–PCR (Figure 10) analysis showed that the mRNA levels of these
genes decreased under DNA-damaging conditions in cells treated with control siRNA.
These data are consistent with earlier studies from Dr. Kleiman’s lab (Mirkin et al., 2008)
and others previous observations (Dheda et al., 2004; Maccoux et al., 2007), which
showed that GAPDH RNA expression can change significantly in different biological
systems and under different conditions, and that these variations can lead to experimental
error between analyzed samples when GAPDH is used as control. Interestingly, the UV-
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induced decrease in the mRNA levels of endogenous housekeeping genes was lost when
the cells were treated with siRNAs targeting PARN (Figure 10).
To determine the role of the BARD1/CstF/PARN complex formation in the
regulation of mRNA levels, I used RNA samples from a stable cell line that expresses a
BARD1 mutant in the threonine 734 (Kim et al., 2006). This mutant has a defect in DNA
damage-induced BARD1 phosphorylation at the T734, which is important not only for
the BARD1/CstF1 complex formation but also for the UV-induced inhibition of both
mRNA 3’ end processing (Kim et al., 2006). A similar pattern of changes in the mRNA
levels of housekeeping genes was observed using the cell line expressing the BARD1
mutant T734A (Figure 10), which did not show BARD1/CstF/PARN complex formation
and activation of deadenylation after UV treatment (Cevher et al., 2010). These results
indicate that BARD1/CstF/PARN complex formation has an important role to decrease
the mRNA levels of housekeeping genes under DNA-damaging conditions, and thereby
might contribute to the UV-induced decrease in the cellular levels of total mRNA. As it
has also been shown that PARN can promote the deadenylation of AU-rich element
(ARE)-containing mRNAs (Lai et al., 2003; Moraes et al., 2006), I also analyzed two
ARE-containing mRNAs, that is, c-fos and c-myc, by qRT–PCR. Both mRNAs increased
transiently under DNA-damaging conditions in cells treated with control siRNA and in a
sarcoma cell line expressing WT BARD1 (Figure 10), in keeping with earlier studies that
indicate that ARE elements within the 3’UTR can control mRNA levels under different
cellular conditions. For example, ARE elements can decrease mRNA stability under nonstress conditions and can increase mRNA stability after UV treatment in mammalian cells
(Blattner et al., 2000; Bollig et al., 2002; Gowrishankar et al., 2005; Wang et al., 2000).
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Figure 10. Analysis of the effect of PARN expression on endogenous gene
expression after UV treatment. Real-time RT-PCR analysis of GAPDH, b-actin, c-fos
and c-myc expression after UV-treatment using RNA samples from cells treated with
control/PARN siRNA and from cells expressing WT/T734A BARD1 mutant. As the RT
products of GAPDH from cells treated with control siRNA and not treated with UV
were used as endogenous control, the log value corresponding to this sample was zero.
The values shown in the figure have been adjusted to avoid the presentation of negative
values. The data shown are the mean±s.e.m. from three independent experiments. Equal
amounts of cDNAs were used in qRT–PCR reactions using primers specific for
-actin, c-fos and c-myc mRNAs. Relative quantification was performed
using standard curves of known amounts of total cDNA. The results shown are the
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average of four PCRs from two different RNA extractions. Taken from Cevher et al.,
(2010)
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Supporting my results, Blattner et al. (Blattner et al., 2000) showed that c-fos
mRNA expression increased 45 min to 1 h after UV treatment and then dramatically
decreased 2 h after UV treatment. Interestingly, PARN knockdown cells and cells
expressing the T734A BARD1 mutant showed increase in the mRNA levels of both c-fos
and c-myc in samples from cells not treated with UV (Figure 10). These results suggest
that the BARD1/CstF/PARN complex has a role in decreasing the levels of short-lived
mRNAs involved in the control of cell growth and differentiation, keeping their
expression levels low under non-stress conditions. Both reduced expression of PARN and
lack of BARD1/CstF/PARN complex formation have a slight effect on the UV-induced
increase in the expression levels of these genes, suggesting that other mechanism(s)
might be involved in determining the mRNA levels of these genes under DNA-damage
conditions. Taken together, these results provide evidence that the BARD1/CstF/PARN
complex has important roles in the regulation of the levels of different endogenous
mRNAs under different cellular conditions. As proposed by Cevher and colleagues
(Cevher et al., 2010), it is possible that the competition between CBP80 and CstF1 for
binding to PARN under different cellular conditions could have a role in regulating the
PARN activity and, therefore, the mRNA levels of different genes.
DISCUSSION
During the DNA repair process, control of gene expression either by transcription
or by RNA processing is important to allow the access of the repair enzymes and to
prevent the formation of deleterious proteins. Following UV irradiation, the cellular
levels of mRNA are transiently decreased (Hanawalt, 1994; Ljungman, 1999). The
cellular mechanisms involved in this response are unknown but imply a functional
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interaction of the DNA repair, transcription, and RNA processing machineries.
Supporting this idea, it has been described that polyadenylation is transiently inhibited
upon UV treatment (Kleiman and Manley, 2001; Kleiman et al., 2005; Mirkin et al.,
2008). As mRNA poly(A) tails are important for regulation of mRNA stability (Mandel
et al., 2008; Shatkin and Manley, 2000; Zhao et al., 1999); changes in the
polyadenylation levels either by activation/inhibition of the reaction or by controlling
the balance between polyadenylation and deadenylation could account for some of the
changes in mRNA levels after UV treatment.
Previous work form Dr. Kleiman’s lab indicated that the polyadenylation factor
CstF1 plays a coordinating role in the nuclear response to UV-induced DNA damage
through its interaction with different factors in different cellular environments (Kleiman
and Manley, 1999, 2001; Kleiman et al., 2005; Mirkin et al., 2008). Cevher and
colleagues (Cevher et al., 2010) discovered that CstF1 interacts with the deadenylation
factor PARN and that this interaction plays a role in inhibition of 3’ cleavage of the
polyadenylation reaction and activation of deadenylation upon DNA damage treatment.
They also found that BARD1 is not only involved in the UV-induced inhibition of 3’
cleavage (Kleiman and Manley, 1999, 2001) but also in the UV-induced activation of
deadenylation in the presence of CstF1. Furthermore, Cevher and colleagues (Cevher et
al., 2010) found that the previously identified nuclear CBP80/PARN deadenylation
inhibitory complex decreased significantly in abundance upon DNA-damaging
conditions, whereas the complex containing CstF1/PARN increased and that CstF1
competed with CBP80 on binding to the same region of PARN. In fact, addition of CstF1
and BARD1 to in vitro deadenylation reactions reverted the CBP80 inhibition effect on
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PARN activity. As part of those studies, I determined that PARN knockdown had an
effect on the stability and polyadenylation of different genes in different cellular
conditions (Figure 10). Taken together, these results suggest that an interplay between
these factors might control gene expression under DNA-damaging conditions by
regulating polyadenylation/deadenylation.
Based on the results presented in the work of Cevher and colleagues (Cevher et
al., 2010), the following regulatory scenario was proposed (Figure 11). In the absence of
DNA damage treatment, CBP80 binds to the C-terminal domain of nuclear PARN and
inhibits its hydrolytic activity to ensure that PARN does not degrade the mRNA (Balatsos
et al. 2006). In this situation, CBC is also known to enhance polyadenylation of premRNAs by increasing the stability of the RNA/CstF complex (Flaherty et al., 1997). As a
result of these functional interactions, polyadenylation takes place and normal levels of
total mRNA are observed. After DNA damage the BRCA1/BARD1-containing complex
is recruited to sites of DNA repair to inhibit mRNA processing by RNAP II
ubiquitination followed by degradation of the large subunit of RNAP II, or by covalent
modification of other element/s of the complex. This facilitates DNA repair and/or
prevent polyadenylation of aborted nascent mRNAs. If the UV-induced inhibition of
mRNA 3’ cleavage is bypassed, the CstF/PARN interaction may provide a fall-back
mechanism to ensure that erroneously polyadenylated mRNAs are eliminated by the
activation of deadenylation. In this situation it has been proposed that CBP80 dissociates
from PARN, allowing PARN to interact with the CstF1/BARD1 complex. This
reorganization will result in an activation of deadenylation and contribute to the

36

P

P

AAAAAAAAAA

2

P

3

P
P

UV

3

P

1

Untreated cells
Long poly(A) tail

A
AAA

2

P

P

1

A

A

A
A

UV-treated cells
Shorter poly(A) tail

Figure 11. A model of poly(A) tail dynamics after DNA damage. In the
absence of DNA damage treatment, CBP80 binds to nuclear PARN, inhibiting its
deadenylase activity. After exposure to UV treatment, the CBP80 protein
dissociates from PARN, allowing binding of PARN to the CstF1/BARD1
complex. As a result of these functional interactions, polyadenylation is inhibited
and a 5’ cap-dependent deadenylation decay pathway is activated, generating a
decrease in the levels of total mRNA. Taken from Cevher et al. (2010)

inhibition of polyadenylation. The final outcome will therefore be that polyadenylation is
inhibited and deadenylation activated, contributing to the observed decrease in the levels
of total mRNA under DNA-damaging conditions. A similar mechanism for control of
gene expression has been described by others. For instance, Kim and Richter (Kim and
Richter, 2006) have shown that the length of the cytoplasmic poly(A) tail is regulated by
polyadenylation/deadenylation under different cellular conditions by the direct interaction
of PARN with the polyadenylation factor CPEB. Moreover, Mauxion et al. (Mauxion et
al., 2008) have shown that the tumor suppressor BTG2 is a general activator of the
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cytoplasmic deadenylases Pop2/Caf1 and Ccr4, and that overexpression of BTG2
accelerates the deadenylation of several reporters and endogenous transcripts, such as
-actin.
It has been shown that PARN co-purifies with essential nonsense-mediated decay
factors (NMD), and that siRNA mediated down-regulation of PARN abrogates NMD
(Lejeune et al., 2003). Although those reports focused on cytoplasmic PARN, it is
possible that the activation of deadenylation by the CstF/PARN/BARD1 complex
formation in the nucleus might signal the degradation of those erroneously
polyadenylated prematurely terminated mRNAs, providing a mechanism of nuclear
mRNA decay. Consistent with this previous work from Dr. Kleiman’s lab showed that
prematurely terminated polyadenylated mRNA transcripts can be detected in vivo
following DNA damage, especially under conditions when the CstF/BARD1/BRCA1
checkpoint is not activated (Mirkin et al., 2008).
Control of polyadenylation/deadenylation in the nucleus could represent a
mechanism to regulate gene expression, which could be important to allow a rapid
response during development or after stress treatment. For example, UV-treatment
induces a decrease in the cellular levels of total mRNA to avoid the expression of
deleterious proteins that may be harmful to the cell (Ljungman, 1999). UV-treatment also
induces stabilization of ARE-containing mRNAs; such as c-fos, kin17, c-jun, IB and cmyc (Blattner et al., 2000), to induce the expression of some proteins involved in DNA
repair and cell cycle. My results indicate that PARN can decrease the stability of
housekeeping genes upon DNA-damaging conditions and of ARE-containing genes upon
non-stress conditions (Figure 10). Consistent with my results, it has been shown that
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ARE-dependent deadenylation plays an important role in the mRNA decay of several
oncogenes involved in regulation of cell growth and differentiation (Blattner et al., 2000;
Lai et al., 2003; Moraes et al., 2006). My results indicate that gene expression of different
genes, such as housekeeping and ARE-containing genes, might be regulated in the
nucleus by the functional interaction between CstF/BARD1, CBP80 and PARN under
different cellular conditions.
As the tumor suppressor BARD1 is involved in this response, it is possible that
malignant cells display altered levels of polyadenylation of certain mRNAs. Supporting
this idea, enhanced polyadenylation has been detected in certain tumor cells (Scorilas,
2002), polyadenylation is inactivated in M phase (Colgan et al., 1996; Colgan et al.,
1998), expression levels of poly(A) polymerase can interfere with cell growth (Zhao and
Manley, 1998). Moreover, antiproliferative transcription factors, such as BTG2 and TOB,
have been shown to enhance deadenylation, and the subsequent mRNA decay (Ezzeddine
et al., 2007; Mauxion et al., 2008). Furthermore, the expression levels of certain AREcontaining genes, such as c-jun and c-fos, increase significantly in cancer cells (Andersen
et al., 2002; Milde-Langosch, 2005; Zajchowski et al., 2001). Interestingly, microRNAs,
which have been either directly involved in human cancers or described as oncogenes or
tumor suppressors, can direct rapid deadenylation of mRNAs and subsequent decay (Wu
et al., 2006; Zhang et al., 2007a).
Taken together, it can be concluded that regulation of the levels of 3’ end
polyadenylation is an important event in controlling cell growth and in the response to
certain stresses, such as UV treatment, and that polyadenylation/deadenylation process
might represent a new mode of global regulation of gene expression.
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CHAPTER III
IDENTIFICATION OF GENES THAT ARE REGULATED BY PARN
DEADENYLATION IN DIFFERENT CELLULAR CONDITIONS
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INTRODUCTION
Almost all eukaryotic mRNA precursors, with the exception of histones, undergo
a cotranscriptional cleavage followed by polyadenylation at the 3′ end. This first round of
polyadenylation is considered a default modification for most mRNAs and confers
stability. In contrast, activation of deadenylation alters the length of poly(A) tails,
affecting mRNA stability, transport, or translation initiation, and hence gene expression
(Zhang et al., 2010). Thus, mechanisms controlling deadenylation are highly regulated
and play key roles in cellular responses, such as mRNA surveillance, DNA damage
response (DDR), and tumor progression, as well as cell development and differentiation
(Cevher and Kleiman, 2010; Cevher et al., 2010; Ji et al., 2009; Mayr and Bartel, 2009;
Singh et al., 2009). Poly(A)-specific ribonuclease (PARN) deadenylase is one of the
major poly(A) specific 3’ exoribonucleases identified in mammalian cells (Copeland and
Wormington, 2001) that plays a role in DDR (Cevher et al., 2010). PARN can interact
with the cleavage stimulation factor 1 (CstF1), and the CstF1/PARN complex formation
has a role in the regulation of gene expression by inhibition of mRNA 3′ cleavage and
activation of deadenylation upon DNA damage (Cevher et al., 2010). PARN, an mRNA
decay enzyme, has been studied extensively in vitro at the biochemical levels but very
little is known of its biological targets and its role in different cellular conditions.
Recently, it has been shown that PARN regulates the expression of genes involved in
mRNA metabolism, transcription, and cell motility in mouse myoblasts (Lee et al., 2012).
My previous studies indicate that the CstF/PARN complex can decrease the mRNA
levels of housekeeping genes under DNA-damaging conditions and of genes involved in
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cell growth and differentiation under non-stress conditions (Figure 10; (Cevher et al.,
2010).
Deadenylation of mRNA is regulated by microRNAs (miRNAs), adenylateuridylate–rich element (ARE) binding proteins, polyadenylation factors, and RNA
binding (RB) factors that recognize cis-acting sequences in the target. About 12% of
mammalian mRNAs bear important regulatory signal AREs in their 3′ untranslated
regions (UTRs), which have been shown to play significant roles in mRNA stability
regulation (Guhaniyogi and Brewer, 2001). PARN has been shown to be involved in
ARE-mediated deadenylation and to promote tristetraprolin (TTP)-directed deadenylation
in vitro (Lin et al., 2007). KH-type splicing regulatory protein recruits PARN to AREcontaining mRNAs to initiate the poly(A) tail shortening that is followed by exosomemediated degradation (Gherzi et al., 2004). Interestingly, tumor suppressors, such as
breast cancer type 1 susceptibility protein (BRCA1) and BRCA1-associated RING
domain protein (BARD1), associated to the polyadenylation factor CstF1 have been
shown to regulate deadenylation by functional interactions with PARN deadenylase
(Cevher et al., 2010).
Recently, work form Dr. Kleiman’s lab showed that the polyadenylation factor
CstF1 can also form a complex with another tumor suppressor and DNA repair factor
with compromised expression on most cancers, p53, resulting in the inhibition of mRNA
3′ cleavage (Nazeer et al., 2011). Downstream signaling in the p53 pathway includes
several cellular responses. The expression of a large number of genes involved in DNA
repair, cell cycle arrest, and/or apoptosis is regulated by transactivating properties of p53.
This occurs via specific DNA binding of the p53 protein to a p53 response element that is
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found either in promoters or introns of target genes (Tokino and Nakamura, 2000).
Transactivation-independent functions of p53 have also been described (Takwi and Li,
2009). For example, certain miRNAs are regulated by p53, and these miRNAs cause
dramatic changes in gene expression, offering an indirect p53-mediated control of gene
expression at the posttranscriptional level (Chang et al., 2007).
Extending those studies, work form Dr. Kleiman’s lab showed that p53 regulates
not only mRNA 3′ cleavage (Nazeer et al., 2011) but also PARN-dependent
deadenylation in different cellular conditions (Devany et al., 2013). As part of these
studies, I also identified the mRNA targets of PARN in non-stress conditions. Together
these results provide evidence of a unique feedback loop between p53 and PARN, in
which PARN deadenylase keeps p53 levels low in non-stress conditions by destabilizing
p53 mRNA through its 3′UTR, and the UV-induced increase in p53 activates PARN,
representing a mechanism of gene expression regulation in a transactivation independent
manner.
RESULTS
As PARN is involved in ARE-mediated deadenylation (Lin et al., 2007),
promotes TTP-directed deadenylation (Lai et al., 2003), and decreases mRNA levels of
ARE-containing genes under non-stress conditions (Figure 10; (Cevher et al., 2010), I
decided to extend these studies and determine which mRNAs might be regulated by
PARN using microarray assays. These assays were performed using RNA samples from
HeLa cells treated with control or PARN siRNAs under non-stress conditions. The RNA
samples were analyzed for gene expression using Affymetrix GeneChip Human Gene 1.0
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ST array, which contains up to 290,000 different transcripts, by the Yale Center for
Genome Analysis. In collaboration with Dr. Bin Tian, UMDNJ-New Jersey Medical
School, we performed pathway analysis of regulated genes using the Ingenuity Systems
applications. Pathway analysis results indicated that the p53 signaling pathway is the
most significantly affected by PARN knockdown in non-stress conditions (Figure 12). In
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Figure 12. PARN deadenylase significantly affects the cellular expression of
genes of the p53 pathway under non-stress conditions. Pathway analysis of
significantly regulated genes by PARN. Nuclear RNA samples isolated from
HeLa cells, treated with siRNAs targeting PARN or control, were analyzed using
the Human Gene 1.0 ST GeneChip (Affymetrix) array. Significant genes were
selected by t test (P value < 0.05). Analysis of canonical pathways was conducted
by using data from Ingenuity Systems (www.ingenuity.com). The bar graph
shows significance of pathway for regulated genes. P values were calculated using
the Fisher’s exact test, and the −log (P value) values are displayed. Only the top
five pathways are shown. Data represent three independent experiments. Taken
from Devany et al., (2013)
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addition, the p53-related gene network was found to be the most significantly regulated
by network analysis and transcription factor analysis (Devany et al.; 2013).
Approximately 75% of genes from the p53 signaling pathway, including p53, were
affected by PARN knockdown, indicating that PARN expression has a specific effect on
the expression of genes associated with p53-mediated signaling in non-stress conditions.
Interestingly, under those conditions 20% of PARN mRNA targets in the p53 signaling
pathway showed both miRNA target site(s) and an ARE(s) in their 3’UTRs (Table 1),
suggesting that PARN might play a role not only in the ARE-mediated but also in
miRNA-mediated deadenylation.
I further confirmed the effect of PARN knockdown on the abundance of several
transcripts in the p53 signaling pathway by quantitative (q)RT-PCR (Figure 13).
Although there was a good correlation between the change observed in the microarray
(Table 1) and that determined by qRT-PCR (Figure 13), the qRT-PCR showed changes of
a greater magnitude than the array. These results support my previous study that showed
that PARN can promote deadenylation and mRNA instability of FBJ osteosarcoma
oncogene and myelocytomatosis oncogene (c-myc; Figure 10; (Cevher et al., 2010),
keeping their expression levels low under non-stress conditions. Because PARN is a
deadenylase, I expected an increase in the steady-state levels of its targets by PARN
knockdown. However, my results show both up- and down-regulation of transcripts,
suggesting complex effects of PARN knockdown on the expression of these mRNAs.

Gene
Symbol

Description

Fold Change

TP53

tumor protein p53
CHK2 checkpoint homolog (S.
pombe)
cyclin-dependent kinase 2
annexin A1
paternally expressed 10
inhibitor of DNA binding 1
FBJ murine osteosarcoma viral
oncogene
v-myc myelocytomatosis viral
oncogene

1.25

1.20
1.22
1.33
1.27
-1.84
-1.49
-1.62
-1.23
-1.47
-1.30
-1.36
-1.93
-1.31
-1.59
-1.48

SERPINE1
HDAC1
CTGF

phosphatase and tensin homolog
retinoblastoma-like 2 (p130)
myosin VI
CD47 molecule
RB1-inducible coiled-coil 1
muscleblind-like 2 (Drosophila)
BCL2-like 1
matrix metallopeptidase 1
thrombospondin 1
leukemia inhibitory factor
SMAD family member 3
interleukin 8
plasminogen activator, urokinase
fibronectin 1
cyclin D3
serpin peptidase inhibitor, clade E
(type 1)
histone deacetylase 1
connective tissue growth factor

CCND1
VEGFA

cyclin D1
vascular endothelial growth factor A

-1.35
-1.75

CHEK2
CDK2
ANXA1
PEG10
ID1
FOS
V-MYC

PTEN
RBL2
MYO6
CD47
RB1CC1
MBNL2
BCL2L1
MMP1
THBS1
LIF
SMAD3
IL8
PLAU
FN1
CCND3

siRNA
PARN/CTRL

1.28
1.62
1.22
1.28
1.25

miRNA targeting sites at the 3’UTR
miR125b, miR504, miR25, miR-30d
miR-24-2

ARE binding
proteins
45
Wig-1, HuR

miR-372, miR-205, miR-885-5p, miR-103, miR-16
miR-21, miR-584, miR-196a and miR-196b
miR-122
miR-206
miR-29b, miR-155, miR-101, miR-221/222, miR-7b,

1.20
miR-26a, miR-24, miR-378, let-7, miR-17-92, miR-145, etc.
1.10

-2.69
-2.04
-1.33

miR-21, miR-17, miR-20a, miR-106b, miR-221, etc.
miR302/367, miR-17, miR-20a, miR-106b, miR-290, etc.
miR-143 and miR-145
miR-34a, miR-155 and miR-326
miR-138
miR-302d, miR-372, miR-200c
miR-21
miR-222
miR-17-92
miR-346, miR-494, miR-199
miR-135a, miR-140-5p, miR-582-3p, miR-582-5p, etc.
miR-146a
miR-193a
miR-200c, miR-29b
miR-16
miR-146a, miRNA-449a/b, miR-30c and miR-301a
miR-449a
miR-17-92, miR-18, miR-19, miR-133 and miR-30
miR-15a, miR-16, miR-302, miR-205, let-7, miR-34a, etc.
miR-297, miR-299, miR-567, miR-609, miR-222, etc.

Table 1. Analysis for the presence of AREs and miRNA targeting sites in the 3’UTRs
of genes from the p53 pathway affected by PARN expression in non-stress conditions.
The expression of 141 genes from the p53 pathway was affected upon siRNA-mediated
knockdown of PARN (Devany et al., 2013). 20% of these genes, including p53, showed
both target sites. ARED 3.0 database and miRWalk were used for the search of AREcontaining mRNAs and miRNAs validated targets (Dweep et al., 2011), respectively.

unknown
unknown
unknown
unknown
unknown
HuR, AUF1,
TTP
HuR, AUF1,
TTP
TTP
unknown
unknown
unknown
unknown
unknown
unknown
unknown
HuR
Unknown
Unknown
unknown
unknown
unknown
unknown
HuR
unknown
HuR
TTP, HuR,
KSRP
HuR
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Figure 13. The effect of PARN knockdown on the abundance of several
transcripts in the p53 signaling pathway by quantitative (q) RT-PCR. qRTPCR analyzing c-fos, c-myc, BCL-XL, HDAC1 and RB1CC1 mRNA levels using
total RNAs samples isolated from cells treated with control/PARN siRNA. qRTPCR determinations give results similar to microarrays with regard to change in
mRNA abundance after PARN knockdown. Taken from Devany et al., (2013)

The microarray analysis showed a 1.25 fold increase in p53 mRNA level of
PARN- to control- siRNA treated HeLa cells (Table 1). Importantly, consistent with the
pathway analysis results, PARN knockdown resulted in a significant increase not only of
p53 mRNA steady-state levels (Figure 14) but also of p53 protein levels (compare lanes 1
and 2 in Figure 14), reaching expression levels similar to that observed after UV
treatment. After UV treatment, the changes in the levels of p53 mRNA and p53 protein
were PARN-independent, indicating there is (are) other mechanism(s) involved in the
regulation of p53 expression during DDR.
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A

B

Figure 14. PARN deadenylase significantly affects the cellular expression of
genes of the p53 pathway under non-stress conditions. (A) p53 mRNA and (B)
protein levels are affected by PARN expression. qRT-PCR and Western blot
analysis of p53 expression after UV treatment using RNA or protein samples,
respectively, from cells treated with control/PARN siRNA. A representative
Western blot from three independent assays is shown. Topo II was used as
loading control. The basal level of the proteins was arbitrarily set at 1.0 in the first
lane, and relative fold change of each protein level is shown below each lane.
Taken from Devany et al., (2013)
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To determine the effect of PARN expression on the stability of p53 mRNA, I
compared mRNA decay rates of p53 transcript in cells treated with control- or PARNsiRNA. The half-life of the p53 transcript was analyzed by qRT-PCR of nuclear RNA
samples taken at different time points from PARN/control siRNA- and actinomycin D
(Act-D)-treated cells (Figure 15). Previous observations have shown a similar half-life for
the p53 transcript (Mazan-Mamczarz et al., 2003). My results indicate that PARN
knockdown stabilized the p53 transcript (Figure 15). Because PARN is a deadenylase, the
stabilization of p53 mRNA by its knockdown might be due to changes in the poly(A) tail
length. Importantly, as shown in Figure 16, siRNA-mediated knockdown of PARN
elongated the poly(A) tail length of p53 mRNA (quantification is shown in Figure 16B).
Together, these results indicate that the PARN deadenylase affects p53 expression by
regulating poly(A) length and hence mRNA stability in non-stress conditions.
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Figure 15. PARN regulates p53 mRNA half-life. mRNA decay rates for p53
and ACTIN, a non-PARN target gene, were determined by qRT-PCR at different
time points following PARN/control siRNA- and Act-D treatment. The relative
half-life of the p53 transcript was calculated from three independent samples.
Errors represent the SD derived from three independent experiments. Western
blot analysis of PARN expression after PARN/control siRNA and Act-D
treatment is also shown. Taken from Devany et al., (2013)

50

A

-200

-100

Rapid Amplification cDNA Ends
poly A Test (RACE-PAT)

-0

-Actin exon 3-4

B

Figure 16. PARN regulates p53 mRNA poly(A) tail length. (A) Nuclear RNA
from PARN/control siRNA-treated cells was reverse-transcribed using an
oligo(dT)-anchor primer and amplified using an oligonucleotide that hybridizes
within the 3′ UTR of p53 mRNA. The products were separated on a nondenaturing
PAGE and detected by ethidium bromide staining. An RT-PCR product from a
non-PARN target gene (ACTIN exon 3–4) was used as a loading control. A
representative PAGE from three independent assays is shown. Molecular weight
standard (MWS, 100-bp ladder from Promega) is also included. (B) Quantification
of poly(A) tail length was done by obtaining the density profile of control and
PARN KD lanes using ImageJ software. Taken from Devany et al., (2013)

51

DISCUSSION
The studies presented in this dissertation contributed to a study that provided
evidence of a unique feedback loop between p53 and PARN deadenylase, in which
PARN keeps p53 levels low in non-stress conditions by destabilizing p53 mRNA, and the
UV-induced increase in p53 activates PARN deadenylase regulating gene expression
during DDR in a transactivation-independent manner. Several lines of evidence support
this model. First, the C-terminal domain of p53 can activate PARN-dependent
deadenylation in vitro and p53 expression levels correlate with levels of mRNA
deadenylation (Devany et al., 2013). Second, those studies show the direct interaction of
the C-terminal domain of p53 with the C-terminal domain of PARN and the existence of
protein complexes of these factors in cellular nuclear extracts (Devany et al., 2013).
Third, PARN significantly affects the cellular expression of genes in the p53 pathway
under non-stress conditions and the stability and poly(A) length of the p53 mRNA
(Figures 12-13 and 15-16). Fourth, PARN knockdown and UV treatment induce a similar
increase in p53 expression (Figure 14). Finally, PARN regulates p53 expression through
the ARE sequence present in the 3′ UTR of p53 mRNA (Devany et al., 2013). Taken
together, these results provide insights into p53 function and the mechanisms behind the
regulation of mRNA 3′ end processing in different cellular conditions.
Together these studies show an alternative mechanism to regulate the expression
levels of p53 based on the control of the steady-state levels of p53 mRNA by PARN
deadenylase under non-stress conditions (Figure 17A). Supporting this, my previous
studies indicate that PARN has a role in decreasing the levels of short lived mRNAs
involved in the control of cell growth, DDR, and differentiation, keeping their expression
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levels low under non-stress conditions (Figure 10, (Cevher et al., 2010). Under stress
conditions, the induction of p53 expression is associated with a decrease in the levels of
total poly(A) mRNA (Ljungman et al., 1999). Because mRNA poly(A) tails are important
for the regulation of mRNA stability, it is possible that these changes of poly(A) mRNA
levels might represent another mechanism of p53-mediated control of gene expression. In
fact, studies from Dr. Kleiman lab indicated that an increase in the expression of p53
inhibits the mRNA 3′ cleavage step of polyadenylation (Nazeer et al., 2011) and induces
PARN deadenylase activity (Devany et al., 2013), suggesting that the p53 associated to
the PARN/CstF/BARD1 complex might regulate gene expression by controlling the
steady-state levels of mRNAs (Figure 17B). Considering that the p53 pathway is tightly
controlled in cells (reviewed in (Vousden, 2006), the p53-associated control of mRNA 3′
processing machinery could represent an indirect mechanism to repress target gene
expression at the posttranscriptional level. The antiproliferative factor BTG2 represents
another example of a general activator of mRNA deadenylation by its direct interaction
with the Pop2–Caf1 and Ccr4 deadenylases (Mauxion et al., 2008). This model is
consistent with the idea proposed by Singh et al. (Singh et al., 2009) that the interaction
of the 3′ processing machinery and factors involved in the DDR/tumor suppression might
result in cell-specific 3′ processing profiles.
Control of deadenylation could represent a mechanism to regulate gene
expression in different cellular conditions, such as development, stress treatment, or
different metabolic conditions. Supporting this idea, recently it has been shown that
PARN regulates the expression of genes involved in mRNA metabolism, transcription,
and cell motility in mouse myoblasts, resulting in PARN-dependent regulation of cell
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motility and wound healing in those cells (Lee et al., 2012). Indeed, the Gene Ontology
analysis presented in this dissertation also revealed significant down-regulation of genes
involved in similar pathways (Table 1, (Devany et al., 2013), such as structure
morphogenesis, cell adhesion, cell migration, and so on. Consistently, the microarray data
presented here showed a decrease in the abundance of mRNA for several genes involved
in cell motility, such as adenosine A2b receptor, ankyrin repeatcontaining domain 54, and
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Figure 17. Model for the regulation of expression of genes in the p53 pathway
by PARN deadenylaseassociated p53 in different cellular conditions. (A)
PARN deadenylase decreases the stability of the p53 mRNA in non-stress
conditions. The AREs in the 3′ UTR of the p53 mRNA have an important role in
this regulatory process. (B) Under DNA damage conditions, p53 protein
accumulates, allowing its association to and activation of PARN deadenylase
resulting in the decrease levels of target mRNAs in the p53-dependent DDR
pathway. Taken from Devany et al., (2013)
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collagen alpha-2 chain in PARN knock-down cells. However, the p53 signaling pathway
was not reported by Lee et al. (Lee et al., 2012), suggesting cell-specific functions of
PARN. Like Lee et al. (Lee et al., 2012), I also observed a decrease in the steady-state
levels of some transcripts by PARN knockdown. However, it is not clear whether this
reflects the function of PARN per se or is the indirect consequence of PARN’s effect on
genes involved in other mRNA metabolic pathways, such as transcription and RNA
processing factors.
The p53 pathway is tightly controlled in cells (reviewed by (Vousden, 2006). The
microarray data presented in this dissertation showed that the expression of 141 genes
from the p53 pathway was affected upon siRNA-mediated knockdown of PARN.
Interestingly, 20% of these PARN target genes, including p53, showed both miRNA
targeting sites and ARE regulatory sequences in their 3’UTR (Table 1). This data
suggests that PARN might mediate the deadenylation of its target mRNAs through both
cis-acting elements present at 3’UTR. This is consistent with the model proposed in Jing
et al. 2005 (Jing et al., 2005) and by myself (Zhang et al., 2010) that both miRNAs and
AREs functionally overlap and contribute to the control of mRNA stability. The
characterization of the regulatory elements in the 3′ UTR of p53 and the factors involved
in this PARN-dependent regulatory pathway may allow us to better understand the
mechanisms that control p53 expression and to find alternative strategies for treating
tumorigenesis and metastasis in various cancers.
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CHAPTER IV
MECHANISMS BEHIND PARN-MEDIATED REGULATION OF THE STEADYSTATE LEVELS OF GENES INVOLVED IN STRESS RESPONSE PATHWAYS
UNDER NON-STRESS CONDITIONS
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INTRODUCTION
Modulation of the length of poly(A) tail of an mRNA by the polyadenylation/
deadenylation machinery is a widespread strategy used to control mRNA stability and
gene expression in different cellular conditions. The dynamic nature of the mRNA 3’-end
processing machinery allows the regulation of the steady-state levels of different mRNAs
and has the potential to contribute to the cells rapid response to stress. Nuclear poly(A)
specific ribonuclease (PARN), a poly(A) specific 3’ exoribonuclease, has been shown to
play a role in DDR. The association of PARN with the cleavage stimulation factor 1
(CstF1) inhibits mRNA 3’ cleavage and activates deadenylation upon UV-induced DNA
damage (Cevher et al., 2010). Besides, PARN is also activated by tumor suppressors and
DNA repair factors with compromised expression on most cancers, such as
BARD1/BRCA1 (Cevher et al., 2010) and p53 (Devany et al., 2013). Interestingly,
PARN regulates the stability of mRNAs of genes involved in DDR, such as c-myc, c-fos,
c-jun, and transcripts in the p53 and BARD1/BRCA1 pathways, keeping their levels low
under non-stress conditions (Cevher et al., 2010; Devany et al., 2013; Moraes et al.,
2006)
Deadenylation, and consequently mRNA stability, is under the control of cisacting regulatory elements present in the 3’ untranslated region (3’UTRs) of eukaryotic
mRNAs, such as alternative polyadenylation (APA) signals, AU-rich elements (AREs)
and microRNA (miRNA) targeting sites. The use of different APA signals generates a
diversity of mRNA isoforms that carry different arrangements of AREs and miRNA
target sites and exhibit different stabilities (Figure 5). Both sequence and location of these
elements are between these cis-acting elements and the 3’ processing machinery is
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highlighted in cancer cells (Mayr and Bartel, 2009; Singh et al., 2009) and during cell
differentiation (Ji et al., 2009; Sandberg et al., 2008; Zlotorynski and Agami, 2008),
where changes in the length of the 3’UTR of different mRNAs affect cell expression
patterns. These sequence elements recruit trans-acting factors that regulate those
processes and affect gene expression, such as miRNA-induced silencing complex
(miRISC), ARE-binding proteins (ARE-BPs), polyadenylation factors, and RNA binding
(RB) factors. Many studies support the idea that miRNAs destabilize mRNA through
deadenylation pathways, while AREs function in mRNA stability by either preventing
mRNA from degradation by exosome or by recruiting the exosome to decrease the
mRNA stability (Zhang et al., 2010).
ARE sequences are frequently present in genes that encode tightly regulated
proteins involved in cell growth regulation, cell differentiation and responses to external
stimuli. The destabilizing functions of AREs are important because in their absence
proto-oncogenes, such as c-fos, c-myc, c-jun, might become oncogenes (Schiavi et al.,
1992). Other mRNAs, such as IL-3, need AREs in order to inhibit the growth of autocrine
tumor mast cells by an immunosuppressant cyclosporin A (Nair et al., 1994). A number
of trans-acting factors, known as ARE-BPs, regulate ARE-mediated decay by either
inhibiting or activating deadenylation, and subsequently change the stability of AREcontaining mRNAs (Barreau et al., 2005). ARE-BPs regulate ARE-mediated decay of
mRNAs by recruiting or blocking the recruitment of the deadenylases to the target
mRNAs in different cellular conditions (Figure 6). PARN has been shown to be involved
in ARE-mediated deadenylation and to promote tristetraprolin (TTP)-directed
deadenylation in vitro (Lin et al., 2007). KH-type splicing regulatory protein (KSRP)
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recruits PARN to ARE-containing mRNAs to initiate the poly(A) tail shortening that is
followed by exosome-mediated degradation (Gherzi et al., 2004).
miRNAs comprise a large family of small, non-coding single-stranded RNAs,
which are predicted to mediate more than 60% of all protein-coding genes in mammalian
cells (Friedman et al., 2009). From protozoans to plants to mammals, miRNAs play key
roles in a broad range of biological processes, in the form of ribonucleoprotein
complexes, known as miRISCs, which deliver miRNAs to their mRNA targets. It is
believed that miRNA function in gene expression regulation mostly through posttranscriptional events, either through translation regulation and/or through deadenylation
activation, which leads to mRNA degradation, and consequently the modulation of gene
expression (Figure 8). It is conventionally accepted that miRNAs function as a negative
regulator of mRNA expression; however, under certain conditions, such as quiescence or
in oocytes, miRNA-mediated upregulation of target mRNAs has also been demonstrated
(Fehr et al., 2012; Truesdell et al., 2012). Interestingly, miRNA-expression profiles
change during DDR (Pothof et al., 2009), suggesting a role of miRNA-mediated pathway
in controlling gene expression during this response.
Briefly, miRISCs are assembled in the cytoplasm where one strand of the mature
miRNA duplex is incorporated along with Argonaute (Ago) proteins, which represent the
catalytic activity, and then the miRISC is directed to its mRNA targets 3’UTR through
interactions with sites of imperfect complementarity (Bartel, 2009; Bushati and Cohen,
2007; Filipowicz et al., 2008; Friedman et al., 2009; Ghildiyal and Zamore, 2009;
Hutvagner and Zamore, 2002; Liu et al., 2004; Martinez et al., 2002; Meister et al.,
2004). Besides 3’UTRs, miRNAs can also modulate cellular gene expression by targeting
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the 5’UTRs, coding regions promoters, and gene termini (Huang et al., 2012; Kim et al.,
2008; Lytle et al., 2007; Place et al., 2008; Tay et al., 2008; Younger and Corey, 2011a,
b). Additional protein components are critical for miRNA-mediated deadenylation. For
example, Ago recruits the GW182 factor (TNRC6 in humans, (Lazzaretti et al., 2009;
Takimoto et al., 2009; Zipprich et al., 2009), and cytoplasmic poly(A) binding protein 1
(PABPC1), both of which contribute to miRNA-mediated poly(A) removal (Fabian et al.,
2009; Jinek et al., 2010; Zekri et al., 2009). One of the best studied deadenylases
involved in miRISCs is the CAF1/CCR4/NOT1 complex (Zekri et al., 2009). Either the
knockdown of CCR4 or NOT1 (Behm-Ansmant et al., 2006; Fabian et al., 2009) or the
overexpression of CCR4 or CAF1 mutants significantly reduce miRNA-mediated
deadenylation and mRNA decay (Piao et al., 2010). Pan2-Pan3 deadenylase has also been
described to promote miRNA-mediated deadenylation and then trigger mRNA decay
(Chen et al., 2009). However, the functional interaction of miRISC and PARN
deadenylase has not been elucidated.
The role of miRNA-mediated deadenylation in different biological processes has
been studied in different systems. For example, it has been shown that let-7-associated
miRISCs directly activate deadenylation of target mRNAs in a cell-free system
(Wakiyama et al., 2007), and that the overexpression of let-7 miRNAs decreases the
mRNA levels of oncogenes, such as c-myc and RAS (Johnson et al., 2005; Sampson et
al., 2007). These results indicate that a decrease in let-7 miRNA levels might lead to
tumorigenicity in lung and colon cancers (Akao et al., 2006; Johnson et al., 2005)). The
processing of let-7 precursors is blocked by lin-28B, a putative RNA-binding protein
highly expressed in hepatocellular carcinoma (Wang et al., 2010). The overexpression of
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lin-28B enhances tumorigenecity by increasing the expression of the oncogenic let-7
targets (Maeda et al., 2010). miR-125b has also been described to participate in miRNAmediated deadenylation and in the reduction of cellular abundance of targeting mRNAs
(Wu and Belasco, 2005). Interestingly, the overexpression of miR-125b correlates with
the downregulation of lin-28 (Eda et al., 2009). These studies indicate that miRNAs
might play crucial roles in multiple oncogenic pathways. In fact, it has been suggested
that miRNAs might function as oncogenes and promote cancer development by
negatively regulating tumor suppressor genes and/or genes that control cell differentiation
of apoptosis (Zhang et al., 2007a; Zhang et al., 2007b); .
While most studies traditionally have focused on cytoplasmic miRNA-mediated
pathways, miRNA’s nuclear functions have begun to emerge in recent years (Cernilogar
et al., 2011; Robb et al., 2005; Tan et al., 2009)). Subcellular localization studies in
mammalian cells have shown that elements from the miRISC, such as Ago-1 and Ago-2,
are localized in the nucleus (Ahlenstiel et al., 2012; Ohrt et al., 2008; Tan et al., 2009).
Nuclear-cytoplasmic shuttling proteins, such as TNRC6A and CRM1, navigate loaded
miRISC into the nucleus, leading miRNA-mediated gene silencing (Nishi et al., 2013). It
has also been shown that elements from the miRISC play a role in transcriptional
regulation (Cernilogar et al., 2011), in alternative splicing (Liu et al., 2012), and in
epigenetic regulation and chromatin organization (Pushpavalli et al., 2012). These
findings reinforce the functional RISC components activity in the nucleus, suggesting
miRNA pathways can be adapted to function in the mammalian nucleus. Deep
sequencing analysis has shown that a subset of miRNAs is predominantly localized in the
nucleus (Liao et al., 2010). In fact, nuclear miRISCs are also able to specifically cleave
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their target mRNAs with high efficiency, resulting in miRNA-mediated gene silencing in
the nucleus (Nishi et al., 2013). Interestingly, nuclear miRISCs are loaded in the
cytoplasm and imported into the nucleus, and their nuclear accumulation depends on the
presence of RNA targets (Ohrt et al., 2008). However, despite the significant progress
made in documenting nuclear miRISC, the mechanism(s) underlying miRNA-mediated
regulation of gene expression in the nucleus (is) are not clear and the participating
nuclear deadenylase and other factors remain(s) to be elucidated.
Interestingly, some of the seed signals recognized by miRNA overlap with AREs
in the 3′UTR (Figure 9). Although the exact contribution of miRNAs, miRISC, AREs and
ARE-BPs to mRNA decay has not been elucidated yet, recent studies have described a
functional overlap between ARE- and microRNA-mediated mRNA turnover pathways. It
has been described that miRNAs can functionally interact with ARE-BPs, and that Dicer
and Ago are required for ARE-mediated decay (Jing et al., 2005). Moreover, it has been
shown that the ARE-BP HuR can bind AREs present in c-myc 3′UTR at a site proximal
to that recognized by let-7 miRNA. HuR appeared to facilitate the targeting of let-7loaded miRISC to an adjacent region of HuR binding site, and to mediate the reduction of
c-Myc mRNA levels (Kim et al., 2009). Another example is the cooperation of ARE-BP
TTP and miR-16 in targeting tumor necrosis factor-α mRNA for ARE-mediated mRNA
degradation (Jing et al., 2005). TTP does not bind directly to miR-16 but it forms a
complex with miRISC, and that complex recruits the deadenylase and the exosome for
mRNA degradation. HuR can also relieve CAT-1 mRNA from miR-122 repression upon
stress in human liver cells (Bhattacharyya et al., 2006).
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As mentioned above, my results indicate that PARN regulates the stability of the
p53 transcript keeping its levels low under non-stress conditions (Cevher et al., 2010;
Devany et al., 2013; Moraes et al., 2006). The tumor suppressor p53 is a nuclear
phosphoprotein that acts as a transcription factor in response to several stress stimuli.
Downstream signaling in the p53 pathway includes numerous cellular responses. The
expression of a large number of genes involved in DNA repair, control of cell cycle and
apoptosis, differentiation, senescence and cellular homeostasis are regulated by
transactivating properties of p53 (Lane and Levine, 2010; Reinhardt and Schumacher,
2012; Vousden and Prives, 2009; Wiesmuller, 2001). This occurs via specific DNA
binding of the p53 protein to a p53 response element that is found either in promoters or
introns of target genes (Tokino and Nakamura, 2000). The p53 pathway can be also
regulated by signaling downstream from p53 (e.g., MDM2, MDM4, INK4/ARF), p53
isoforms (e.g., p63, p73), and microRNAs (e.g., miR-34). Transactivation-independent
functions of p53 have also been described (Takwi and Li, 2009). For example, certain
miRNAs are regulated by p53, and these miRNAs cause dramatic changes in gene
expression, offering an indirect p53-mediated control of gene expression at the
posttranscriptional level (Chang et al., 2007). Although many reports have been
published about control of p53 protein expression and its effect on downstream pathways,
very little is known of the mechanisms behind the control of p53 mRNA steady-state
levels in different conditions (Vilborg et al., 2010) .
In this study, I found that PARN deadenylase regulates the mRNA stability of one
of its targets, the p53 mRNA (Devany et al., 2013), via a nuclear miRNA-mediated
pathway. I found that Ago-2 activates PARN deadenylase activity by directly interacting
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with the N-terminal domain of PARN and forming a complex in the nucleus.
Interestingly, the binding of PARN to the p53 mRNA 3’UTR depends on cis-acting
signals present in this region, such as AREs and miRNAs target sites, and Ago-2
expression. I showed that the miR-125b-loaded miRISC recruits PARN to the target p53
mRNA leading to a change in p53 mRNA steady-state level. These results reveal a novel
regulatory pathway wherein PARN deadenylase plays a role in not only ARE- but also
miRNA-mediated regulation of mRNA stability and, consequently, expression level. This
regulatory pathway indicates a novel nuclear function of miRISC in mammalian cells as
well as provides new insights in the p53 pathway.
RESULTS
PARN regulates p53 expression through its association with p53 3’UTR.
Previously, I have shown that PARN plays a role regulating p53 mRNA steadystate level through destabilizing p53 transcript (Figures 14-16 and Table 1, (Devany et
al., 2013). In this part of study, I investigated the mechanisms underlying regulation of
p53 mRNA stability by PARN deadenylase. First I tested if PARN could associate with
p53 mRNA under non-stress conditions. RNA immunoprecipitation (RIP) assays using
antibodies against PARN showed that p53 mRNA can form a complex with PARN in
samples from cross-linked RKO cells (Figure 18), indicating that PARN can regulate p53
mRNA stability by, most probably, an indirect association to the 3′ UTR. RIP assays also
showed that PARN can form a complex with c-myc RNA (Figure 18), which is another
target of PARN deadenylase (Cevher et al., 2010).
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As most of the regulatory elements involved in PARN-mediated regulation of
mRNA stability are located in the 3′ UTR of the genes, I decided to determine whether
the PARN-induced decrease of p53 mRNA levels under non-stress conditions is through
this region of p53. Firefly luciferase plasmids were constructed in a way that luciferase
gene is under the control of either the wild type p53 3′ UTR or the vector 3′UTR (Figure
19A). Recently, a G-quadruplex structure that protects the p53 mRNA from degradation
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Figure 18. PARN can interact with p53 and c-myc under non-stress
conditions. (A) RIP of endogenous genes from RKO cells. The extracts were
immunoprecipitated with either anti-PARN or IgG antibodies. The endogenous
nuclear RNA immunoprecipitated with the antibodies was quantified by qRTPCR using primers specific for each gene. (B) The bar graph indicates the
quantification of RNA immunoprecipitated with the indicated antibodies. The
qRT-PCR values were calculated from three independent samples. Taken from
Devany et al. (2013)
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upon stress by binding to heterogeneous nuclear ribonucleoprotein H/F has been
described (Decorsiere et al., 2011). This structure, which is located downstream of the 3′
cleavage site, was not included in this luciferase construct. To investigate the role of p53
expression in these luciferase assays, I used a group of isogenic cell lines that express
different levels of p53: the colon cancer HCT116 and p53-null HCT116 cell lines and the
colon carcinoma RKO and RKO-E6 (low p53 levels) cell lines. A significant increase in
firefly/Renilla ratio for the construct with the p53 3′UTR relative to the control construct
was detected in RKO/RKO-E6 and HCT116/HCT116 p53−/− cells treated with PARN
siRNA (Figure 19B). RKO/RKO-E6 and HCT116/HCT116 p53−/− cells showed similar
ratios for the expression of firefly/Renilla luciferase indicating that the PARN-mediated
regulation of p53 expression is p53-independent.
Since PARN could associate with p53 transcript, and its role in the control of p53
expression is through p53 mRNA 3’UTR region, next I tested if PARN binds to p53
mRNA at its 3’UTR. Constructs carrying the p53 3’UTR (luc-p53) or not (luc-vector)
were transfected into RKO cells. Then RIP assays using antibodies against PARN or IgG
were performed followed by qRT-PCR with luciferase primers for quantification. The
RIP assays indicate that PARN can form a complex with the luciferase mRNA carrying
the 3′ UTR of p53 (Figure 19). Interestingly, the 3′ UTR of p53 mRNA also contains
ARE that associates with ARE-binding proteins, such as wild-type p53-induced gene 1
(Vilborg et al., 2009) and HuR (Zou et al., 2006) and regulates p53 mRNA steady-state
levels. Importantly, it has been shown in Dr. Kleiman’s lab that the replacement of the
ARE sequence from the p53 3′ UTR (noARE construct) significantly increased the
firefly/Renilla ratio compared with the WT p53 3′ UTR construct (Devany et al., 2013),
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Figure 19. PARN regulates p53 expression through ARE sequence present in
the 3′ UTR of p53 mRNA. (A) Diagram of firefly luciferase reporter constructs
with the vector or 3′ UTR sequence from the p53 gene. Polyadenylation signals
(PAS) are indicated. (B) Constructs carrying the p53 3′ UTR (p53) or not (vector)
were transfected in cells treated with PARN or control siRNAs. The ratios of the
firefly/Renilla values for the p53 construct relative to the vector construct are
shown. The firefly/Renilla values were calculated from three independent
samples. Errors represent the SD derived from three independent experiments.
Taken from Devany et al., (2013)

showing that the AREs can decrease mRNA stability and hence expression of the
luciferase-p53 3′ UTR construct. Interestingly, those studies showed that the siRNA
mediated knockdown of PARN only increases the expression ratio of firefly/Renilla
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luciferase from the constructs carrying the AREs but not from the constructs without the
AREs, indicating that the AREs in the p53 3′ UTR are necessary for PARN-mediated
regulation of p53 expression. Supporting this idea, RIP assays presented in this
dissertation indicate that PARN can form a complex with the luciferase mRNA carrying
the 3′ UTR of p53 and this is abolished when AREs are replaced by other sequences
(Figure 20). Together, these results indicate that the ARE in the p53 3′UTR is important
for the PARN-mediated regulation of p53 mRNA steady-state levels and that this
regulation is p53-independent.
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Figure 20. PARN can interact with p53 3’UTR under non-stress conditions.
RIP of cells transfected with luciferase constructs carrying either the p53 3’UTR
(luc-p53) or not (luc-vector). A construct with the ARE-replaced in the p53 3′
UTR (noARE) was also analyzed. The extracts were immunoprecipitated with
either anti-PARN or IgG antibodies. Nuclear RNA immunoprecipitated with the
antibodies was quantified by qRT-PCR using primers specific for luciferase gene
and actin gene.
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The miRISC component Ago-2 binds to PARN deadenylase in the nucleus.
PARN regulates the stability of ARE-containing mRNAs keeping their levels low
under non-stress conditions (Cevher et al., 2010; Devany et al., 2013; Moraes et al.,
2006)). Interestingly, 20% of PARN mRNA targets in the p53 signaling pathway showed
not only AREs but also miRNA target sites in their 3’UTRs (Chapter III, Table 1). RNAbinding proteins, such as ARE-binding proteins and elements of the miRISC, are
necessary to recruit an active deadenylase to its mRNA substrates leading to mRNA
deadenylation and degradation. Although the miRISC has been shown to functionally
interact with several deadenylases, its functional interaction with PARN has not been
elucidated. To test the possibility that elements of the miRISC might also be involved in
PARN-dependent deadenylation, I analyzed the potential interaction of PARN and Ago2. First, the localization of Ago-2 and PARN in cellular fractions from HCT116 cells was
analyzed (Figure 21). Both Ago-2 and PARN were present in the nuclear fraction.
Topoisomerase II (Topo II) and actin were used as subcellular fractionation controls. As
nuclear deadenylation is activated upon UV-induced DNA damage (Cevher et al., 2010),
I have included stress conditions in this study. Interestingly, Ago-2 shuttled between the
nuclear and cytoplasmic compartment in response to UV treatment, indicating a dynamic
intracellular distribution of Ago-2 in response to DNA damage and suggesting a possible
role of miRNA pathway in control of gene expression during DDR. The previously
described UV-induced increase in nuclear PARN (Cevher et al., 2010) was also observed.
To test whether PARN physically associates with Ago-2 I performed coimmunoprecipitation (co-IP, Figure 22) and pull-down (Figure 23) assays. The co-IPs
indicate that PARN can form (a) protein complex(es) with Ago-2 in nuclear extracts (NE)
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Figure 21. Both PARN and the miRISC component Ago-2 are present in the
nuclear fraction. Both PARN and Ago-2 are present in the nuclear fraction. Ago2 shuttles between the nuclear and cytoplasmic compartment in response to UV
irradiation. Equivalent amounts of cytoplasmic and nuclear fractions of HCT116
cells were subjected to SDS-PAGE and proteins were detected by immunoblotting
using antibodies against Ago-2 and PARN. Both nuclear (nPARN) and
cytoplasmic (cPARN) isoforms of PARN are shown. Topo II and actin are used as
subcellular fractionation control. The basal level of the proteins was arbitrarily set
at 1.0 in the first lane, and relative fold change of each protein level is shown
below each lane. Quantifications were done with Image J software
(http://rsb.info.nih.gov/ij/).

from HCT116 cells. Interestingly, the complex was detected in both non-stress conditions
and after UV treatment. As samples were treated with RNase A, the observed interactions
were probably not due to an RNA tethering effect. The results showed that PARN can
interact directly with Ago-2 and that the N-terminal domain, which contains the nuclease
activity and is responsible for cap-binding properties of PARN (Martinez et al., 2001), is
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important for this interaction (Figure 23). Together these results indicate that PARN can
interact with the miRISC component Ago-2 to form (a) complex(es) independently of
miRNA and stress conditions.
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Figure 22. The miRISC component Ago-2 interacts with PARN deadenylase
to form a protein complex in the nucleus. PARN and Ago-2 could form (a)
complex(es) in NEs of HCT116 cells independently of UV treatment. The NEs
were immunoprecipiated with anti-PARN (Left) and anti-Ago-2 (Right).
Equivalent amounts of the pellets (IP) and supernatants (SN) were resolved by
SDS-PAGE and proteins were detected by immunoblotting using antibodies
against PARN and Ago-2. Antibody against Topo II was used as a control.

71

input
-His-PARN

input

-His-NTD-PARN

-GST-Ago-2

-PARN
1

2

3

-His-CTD-PARN
1

2

3

4

5

6

7

8

9

Figure 23. The miRISC component Ago-2 interacts directly with PARN
deadenylase in vitro. Ago-2 interacts directly with the N-terminal domain of
PARN. Immobilized His-PARN on nickel beads was incubated with GST-Ago-2
(left panel). Bound proteins were eluted, detected by Western blotting with
antibodies against PARN or Ago-2. 5% of His-PARN and GST-Ago-2 used in the
reaction are shown as input. Immobilized GST-Ago-2 or GST on glutathione
beads were incubated with full-length (FL), N-terminal domain (NTD) or Cterminal domain (CTD) of His-PARN (right panel). Bound proteins were detected
by immunoblotting as before. 5% of His-PARN derivatives used in the reaction
are shown as input.
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Ago-2 has a role in the UV-induced activation of nuclear PARN deadenylase
activity.
To test whether Ago-2 has a direct influence on PARN deadenylase activity I
performed in vitro reconstituted deadenylation assays, where I monitored the
deadenylation of a radiolabeled L3(A30) RNA substrate in a reaction using limiting
amounts of His-PARN and increasing amounts of GST-Ago-2. Addition of GST-Ago-2
enhanced the deadenylation activity of PARN up to 2.3 folds (Figure 24), indicating that
Ago-2 is an activator of PARN activity in a cell-free system and in the absence of
miRNA. Importantly, deadenylation activity was not detected when using GST-Ago-2
alone. Extending these results, I investigated the role of Ago-2 in nuclear deadenylation
by performing siRNA mediated knockdown of Ago-2 in HCT116 cell line and then
analyzing the UV-induced activation of deadenylation. As described in previous studies
(Cevher and Kleiman, 2010; Devany et al., 2013), Figure 25 shows that deadenylation
activity in NEs of HCT116 cells treated with control siRNA increased significantly after
UV treatment. Interestingly, deadenylation, especially after UV-treatment, was
completely abolished in samples from cells treated with siRNA targeting Ago-2. These
results indicate that in the presence of Ago-2, which is involved in cytoplasmic
deadenylation processes, PARN-mediated deadenylation is activated both in vitro and in
samples from HCT116 cells. Together these results suggest that Ago-2/PARN complex
formation activates PARN deadenylase and, therefore, might regulate gene expression.
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Figure 24. Ago-2 enhances PARN-mediated deadenylation in vitro. Ago-2 can
activate PARN-dependent deadenylation in vitro. Deadenylation assays were
performed in the presence of radiolabeled capped L3(A30) RNA substrate as
described (Cevher et al., 2010), using different concentrations of His-PARN and
increasing amount of GST-Ago-2. Positions of the polyadenylated RNA L3(A30)
and the L3 deadenylated product are indicated. Numbers beneath gel lane indicate
relative deadenylation (RD), which was calculated as [L3 fragment/(L3(A30) + L3
fragment)] x 100. Quantifications were done with Image J software.
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Figure 25. siRNA mediated knockdown of Ago-2 abolishes UV-induced
activation of deadenylation. siRNA-mediated knockdown of Ago-2 abolishes
UV-induced activation of deadenylation in HCT116 cells. The protein levels of
Ago-2 and Topo II were analyzed by Western blotting after Ago-2/control siRNA
treatment (Left). A representative deadenylation reaction from three independent
assays is shown (Right). NEs from HCT116 cells treated with Ago-2/control
siRNA and UV irradiation, and allowed to recover for 2 h were analyzed for
radiolabeled L3(A30) deadenylation as described (Cevher et al., 2010). RNAs
were extracted and deadenylation reactions were analyzed as in Figure 24.
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Association of PARN to its target mRNAs requires Ago-2.
As Ago-2 is the core component of the miRISC complex, which delivers miRNAs
and deadenylases to their mRNA targets, and my results indicate that it binds directly to
PARN enhancing its deadenylase activity (Figures 22-25), I wonder whether Ago-2 plays
a role in PARN-mediated expression regulation of p53, one of its targets, under nonstress conditions. To test these NEs from HCT116 cells treated with control, PARN, Ago2 or both PARN/Ago-2 siRNAs were analyzed by Western blot for p53 expression.
Interestingly, p53 protein levels increased in samples from cells treated with either Ago-2

fold change in p53 expression levels
(siRNA/control ratio)

or PARN siRNA (Figure 26), suggesting that both factors might be involved in the same
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Figure 26. siRNA-mediated knockdown of Ago-2 and PARN have similar
effects on p53 expression levels. NEs from HCT116 cells treated with control,
PARN, Ago-2, or both PARN/Ago-2 siRNAs were analyzed by Western blot for
p53 expression. Topo II was used as loading control (not shown). The p53 protein
expression levels were calculated from three independent samples. The basal level
of the proteins was arbitrarily set at 1.0 in the control siRNA-treated sample.
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p53 regulatory pathway. In fact, the double knockdown of PARN and Ago-2 resulted in
similar p53 protein levels to Ago-2 knockdown alone indicating that Ago-2 is necessary
for PARN-mediated reduction of p53 protein levels.
Next, I tested whether Ago-2 could facilitate the recruitment of PARN to its
mRNA targets. My previous studies indicated that PARN can regulate the steady-state
levels of ARE-containing mRNAs, such as p53 and c-myc, by indirect association to their
transcripts under non-stress conditions (Devany et al., 2013). To examine the possible
role of Ago-2 in recruiting PARN deadenylase to its mRNA targets, RNA
immunoprecipitation assays were performed using samples from HCT116 cells treated
with either control or Ago-2 siRNA (Figure 27). Consistent with my previous results
(Devany et al., 2013), using antibodies against PARN, the RIP assays showed that both
p53 and c-myc mRNAs formed a complex with PARN in samples from control siRNAtreated cells (Figure 27). Interestingly, siRNA-mediated knockdown of Ago-2 reduced
the interaction of PARN with both p53 mRNA and myc mRNAs. To confirm these
results, one student at Dr. Kleiman’s lab, Emral Devany, performed RNA pull-down
assays using an in vitro transcribed biotinylated RNA carrying the p53 3’UTR sequence
and NEs from HCT116 cells treated with Ago-2 or control siRNAs (personal
communication, not shown). Supporting my results, her studies indicate that RNA
encompassing p53 3’UTR pulled-down PARN from samples of control siRNA-treated
cells, and this RNA-PARN interaction significantly decreased when samples from Ago-2
siRNA-treated cells were used in the assay.
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Figure 27. Ago-2 is required for the association of PARN to its target mRNAs
under non-stress conditions. NEs from HCT116 cells treated with Ago-2/control
siRNA were prepared after formaldehyde crosslinking. The extracts were
immunoprecipitated with either antibodies against PARN or control IgG. The
endogenous nuclear RNA immunoprecipitated was quantified by qRT-PCR using
primers specific for p53 and myc gene. The qRT-PCR values were calculated
from three independent samples.

To rule out the possibility that the effect of depletion of Ago-2 on reducing PARN
association with p53 mRNA 3’UTR is due to the cell-wide response to low levels of Ago-2
expression, Emral Devany also performed RNA pull-down assays using an in vitro transcribed
biotinylated RNA encompassing WT p53 3’UTR, NEs from HCT116 cells treated with Ago-2
siRNA and increasing amounts of recombinant Ago-2. Interestingly, increasing amounts of
recombinant Ago-2 in the incubation system increased the amounts of PARN detected in the p53
3’UTR pull-down fraction (personal communication, not shown). Together, these results suggest
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that Ago-2 might play a critical role in PARN-mediated regulation of gene expression by
recruiting PARN to its target mRNAs.

PARN regulates p53 expression through not only ARE but also miRNA targeting
site present in the 3’UTR of p53 mRNA.
It is known that PARN is involved in ARE-mediated deadenylation (Korner and
Wahle, 1997; Lai et al., 2003; Lin et al., 2007). My studies have shown that Ago-2
activates PARN deadenylase through direct protein interaction (Figures 22-25) and
participates in recruiting PARN to some of its mRNA targets (Figure 27), suggesting that
PARN might play a role not only in ARE- but also miRNA-mediated deadenylation.
Supporting this, others have shown the functional overlapping of ARE- and miRNAmediated regulatory pathways (Bhattacharyya et al., 2006; Jing et al., 2005; Kim et al.,
2009). Interestingly, p53 mRNA contains both miRNA targeting sites (miR-504, miR125a/miR-125b, and miR25/miR30d) and AREs at its 3’UTR, and some of these signals
overlapped as showed in Figure 28. To test whether both AREs and miRNA targeting
sites are involved in the PARN-associated Ago-2-mediated regulation of p53 mRNA
steady-state levels under non-stress conditions constructs were generated that have the
luciferase gene under the control of WT p53 3’UTR or replacement mutants in AREs
and/or miRNA targeting sequences that are in close proximity in the p53 3’UTR (Figure
29). More specifically, I focused my studies on miR-504 (Hu et al., 2010; Le et al., 2009)
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CATTCTCCACTTCTTGTTCCCCACTGACAGCCTCCCACCCCCATCTCTCCCTCCCCTGCCATTTTGGGTTTTGGGTCTTTGAACC
CTTGCTTGCAATAGGTGTGCGTCAGAAGCACCCAGGACTTCCATTTGCTTTGTCCCGGGGCTCCACTGAACAAGTTGGCCTGCA
miR-25

CTGGTGTTTTGTTGTGGGGAGGAGGATGGGGAGTAGGACATACCAGCTTAGATTTTAAGGTTTTTACTGTGAGGGATGTTTGGG
AGATGTAAGAAATGTTCTTGCAGTTAAGGGTTAGTTTACAATCAGCCACATTCTAGGTAGGGGCCCACTTCACCGTACTAACCAG
miR-30d

GGAAGCTGTCCCTCACTGTTGAATTTTCTCTAACTTCAAGGCCCATATCTGTGAAATGCTGGCATTTGCACCTACCTCACAGAGT
GCATTGTGAGGGTTAATGAAATAATGTACATCTGGCCTTGAAACCACCTTTTATTACATGGGGTCTAGAACTTGACCCCCTTGAG

GGTGCTTGTTCCCTCTCCCTGTTGGTCGGTGGGTTGGTAGTTTCTACAGTTGGGCAGCTGGTTAGGTAGAGGGAGTTGTCAAGT
CTCTGCTGGCCCAGCCAAACCCTGTCTGACAACCTCTTGGTGAACCTTAGTACCTAAAAGGAAATCTCACCCCATCCCACACCC
miR-504

TGGAGGATTTCATCTCTTGTATATGATGATCTGGATCCACCAAGACTTGTTTTATGCTCAGGGTCAATTTCTTTTTTCTTTTTTTTT
miR-125b

AU-Rich element

TTTTTTTTTCTTTTTCTTTGAGACTGGGTCTCGCTTTGTTGCCCAGGCTGGAGTGGAGTGGCGTGATCTTGGCTTACTGCAGCCT
TTGCCTCCCCGGCTCGAGCAGTCCTGCCTCAGCCTCCGGAGTAGCTGGGACCACAGGTTCATGCCACCATGGCCAGCCAACT
TTTGCATGTTTTGTAGAGATGGGGTCTCACAGTGTTGCCCAGGCTGGTCTCAAACTCCTGGGCTCAGGCGATCCACCTGTCTCA
GCCTCCCAGAGTGCTGGGATTACAATTGTGAGCCACCACGTCCAGCTGGAAGGGTCAACATCTTTTACATTCTGCAAGCACATC
TGCATTTTCACCCCACCCTTCCCCTCCTTCTCCCTTTTTATATCCCATTTTTATATCGATCTCTTATTTTACAATAAAACTTTGCTG
CCACCTGTGTGTCTGAGGGGTG

AU-Rich element

Figure 28. Sequence of p53 mRNA 3’UTR. miR-binding sites and AU-rich
elements (AREs) are shown. miR-125b binding site (red) and miR-504 binding
site are adjacent to an ARE (blue).
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and miR-125b (Le et al., 2009) that are located next to the ARE (Vilborg et al., 2009;
Zou et al., 2006) in the p53 3′UTR that is important for PARN binding and PARNmediated regulation of p53 mRNA steady-state levels (Figure 20; (Devany et al., 2013).
Interestingly, the siRNA-mediated knockdown of PARN significantly increased the ratio
of firefly/renilla luciferase activity from the constructs carrying the WT p53 3’UTR but
the effect of PARN knockdown was completely abolished when the AREs (noARE),
miRNA target site (nomiR) or both (noBOTH) signals are replaced by other sequences
(Figure 30). Together, these results indicate that both regulatory signals at the p53 3’UTR
are necessary for PARN-mediated regulation of p53 expression.
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Figure 29. Diagram of firefly luciferase reporter constructs with different
3’UTR sequences from the p53 gene. Polyadenylation signals (PAS) are
indicated.

PAS

vect

Firefly Luciferase

PAS

SV40
enhancer

ARE

Luc-p53

PARN siRNA /control ratio

81
3

2

1

0

Figure 30. Both miRNA targeting sites and AREs are critical for PARNmediated regulation of p53 expression. Constructs carrying the p53 3’UTR (p53)
or ARE (noARE), miR-125b targeting site (nomiR) or both signals (noBOTH)
replaced p53 3’UTR were transfected into HCT116 cells. Luciferase assays were
done in cells treated with control or PARN siRNA. The ratio of the firefly/Renilla
values obtained for each construct in PARN knockdown cells relative to control
siRNA-treated cells are shown. The firefly/renilla values were calculated from three
independent samples. Errors represent the SD derived from three independent
experiments.

Next, I examined whether PARN physically associates with p53 mRNA through
ARE and/or miRNA targeting sites in the 3’UTR. First, several cell lines were used to
test if ARE sequence present at the p53 mRNA 3’UTR is critical for the interaction of
PARN with p53 mRNA. Consistent with my previous studies (Figure 20), the RIP assays
indicated that PARN can form a complex with the luciferase mRNA carrying the 3’UTR
of p53 and this is abolished when AREs are replaced by other sequences (Figure 31).
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RKO/RKO-E6 and HCT116/HCT116 p53-/- cells showed similar ratios for the RIP
assays with different constructs, indicating that the PARN-mediated regulation of p53
expression and PARN binding to AREs are p53 independent.
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Figure 31. ARE sequences present in the 3′ UTR are involved in the interaction
of PARN with p53 mRNA under non-stress conditions. RIP analysis of samples
cells transfected with luciferase constructs carrying either the p53 3′ UTR (p53) or
ARE-replaced p53 3′ UTR (noARE). Nuclear extracts were immunoprecipitated
with either anti-PARN or IgG antibodies. The endogenous nuclear RNA
immunoprecipitated with the antibodies was quantified by qRT-PCR using primers
specific for the luciferase gene. The ratio of the fold change for p53/no-ARE RNA
values obtained for each construct is shown. The qRT-PCR values were calculated
from three independent samples.
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Extending these studies, the RIP assays indicate that PARN cannot form a
complex with the luciferase mRNAs carrying the 3’UTR of p53 with replaced sequences
in the AREs or/and miRNA targeting sites (Figure 32). Importantly, the interaction of
PARN with the luciferase mRNA carrying the 3’UTR of p53 is lost in HCT116 cells
treated with Ago-2 siRNA, indicating that Ago-2 knockdown and the replacement of the
3’UTR signals had a similar effect on the interaction of with p53 3’UTR. Together these
results support the idea that miRNA-associated Ago-2 and ARE might be part of the
same PARN-mediated regulatory pathway. Moreover, RNA pull-down assays using
RNAs encompassing either WT p53 3’UTR or the mutant variants of p53 3’UTRs, and
NEs from HCT116 cells showed that the RNA-PARN interaction depended on the
presence of both the ARE sequence and miRNA targeting site (Figure 33). As expected,
the interaction of Ago-2 with the RNA was not decreased by the replacement of the ARE.
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Figure 32. Ago-2 expression and cis-acting signals present in the 3’UTR of
p53 mRNA are involved in the association of PARN with p53 mRNA 3’UTR.
RIP assays were performed using samples from HCT116 cells treated with Ago2/control siRNAs and transfected with the luciferase constructs described in
Figure 29.
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Figure 33. Both ARE and miR-125b targeting signal at the 3’UTR are
necessary for PARN to target at p53 mRNA. RNA pull-down assays were
performed using biotinylated RNA carrying WT or signal replaced (noARE,
nomiR, and noBOTH) 3’UTR of p53 and NEs from HCT116 cells. A
representative pull-down reaction from three independent assays is shown.

85

PARN functionally interacts with miR-125b-associated Ago-2.
Then I tested whether miRNAs play a role in the PARN-mediated regulation of
p53 mRNA stability in the nucleus of human cells. I studied miRNAs, such as miR-504,
miR-125b, and miR25/30d, that have been previously shown to have a target site in p53
3’UTR and to downregulate p53 expression (Hu et al., 2010; Kumar et al., 2011; Le et
al., 2009)). First, the effect of UV-treatment on the abundance of these miRNAs was
determined in samples from HCT116 cells by qRT-PCR analysis of total and nuclear
RNA samples. Consistent with previous reports (Le et al., 2009; Pothof et al., 2009; Tan
et al., 2012), the total amount of each miRNA showed a change of different magnitude
after DNA damage (Figure 34). Changes in the abundance of these miRNAs were also
observed in the nuclear RNA samples in response to DNA damage. As described before
(Kim et al., 2008), these results also showed the enrichment of miR-320 in nuclear
fractions.
To examine whether PARN associates with these miRNAs, nuclear lysates from
HCT116 cells were immunoprecipitated with an antibody against PARN or control IgG
followed by RT-qPCR detection of miRNAs. Interestingly, RIP assays indicate that under
non-stress conditions miR125b was significantly enriched in PARN-IP (Figure 35). Both
miR-30d and miR-504 also showed some association with PARN. Remarkably, all p53
3’UTR targeting miRNAs show dramatic decrease in PARN association in response to
UV-induced DNA damage, suggesting that PARN might have a critical role in miRNAmediated downregulation of p53 expression under non-stress conditions. miR320, which
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Figure 34. Abundance of p53 targeting miRNAs in response to UV
irradiation. Nuclear and total RNAs from UV treated HCT116 cells were
isolated and miRNA abundance was assessed by qRT-PCR using a specific kit for
miRNA analysis.
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does not target at p53 3’UTR, was used as control for binding specificity. These results
are consistent with our previous report (Devany et al., 2013) that showed that p53 mRNA
and p53 protein levels are regulated by PARN under non-stress conditions and are
PARN- independent after UV treatment.
To examine the role of miR-125b in PARN-mediated p53 mRNA decay HCT116
cells were transfected with miR-125b inhibitor expression plasmid, which blocks
endogenous miR-125b, or control plasmid and analyzed p53 mRNA steady-state levels.
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Figure 35. PARN association to different p53 targeting miRNAs is favored in
non-stress conditions. RIP assays were performed as described in Material and
Methods. Nuclear miRNAs immunoprecipitated were quantified by qRT-PCR.
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In Figure 36, the functional knockdown of miR-125b showed an increase in p53 mRNA
(upper panel) and protein levels (lower panel). A similar increase in both p53 mRNA and
p53 expression was determined after PARN-knockdown (Devany et al., 2013).
Importantly, as shown in Figure 37A, the functional inhibition of miR-125b elongated the
poly(A) tail length of p53 mRNA (quantification is shown in Figure 37B), indicating
miR-125b regulates p53 mRNA steady-state level through modulating its poly(A) tail
length.
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Figure 36. Functional knockdown of miR-125b increases p53 mRNA and
protein levels. Samples from HCT116 cells transfected with miR-125b inhibitor
expression plasmids or control vectors were analyzed for p53 mRNA levels by
qRT-PCR and for p53 protein levels by Western blot.
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Figure 37. miR-125b regulates p53 mRNA poly(A) tail length. Nuclear RNAs
from HCT116 cells transfected with miR-125b inhibitor expression/control
vectors were reverse-transcribed using an oligo(dT)-anchor primer and amplified
using an oligonucleotide that hybridizes within the 3’UTR of p53 mRNA. The
products were separated on a non-denaturing PAGE and detected by ethidium
bromide staining. An RT-PCR product from a non-PARN target gene (ACTIN
exon 3–4) was used as a loading control. A representative PAGE from three
independent assays is shown. Molecular weight standard (MWS, 100 base pair
ladder from Promega) is also included.

Then I tested whether miR-125b is involved in PARN association with p53
mRNA. Nuclear lysates from HCT116 cells transfected with miR-125b inhibitor
expression or control plasmids were used for miRNA-IP assays using PARN antibodies.
The RIP assays showed that the functional expression of miR-125b increased the binding
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of PARN to p53 mRNA (Figure 38). To further assess the regulatory function of miR125b in miRNA-mediated deadenylation, NEs from HCT116 cells transfected with miR125b inhibitor or control vectors were analyzed for deadenylation assays. These assays
were performed using an in vitro transcribed, radiolabeled, capped and polyadenylated
(A20) RNA encompassing the the WT p53 3’UTR (Figures 39A) and the mutants
described in Figure 29 (Figures 39B). Importantly, samples from cells with function loss
of miR-125b showed a decrease in the deadenylation of WT p53 3’UTR (Figure 39A),
indicating miR-125b is important to promote miRNA-mediated deadenylation of p53
mRNA. In Figure 39B, the deadenylation assays showed that the presence of the

fold change of p53 mNRA in PARN IP

targeting sequence was important for this miR-125b-mediated deadenylation of p53.
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Figure 38. Functional loss of miR-125b attenuates p53 mRNA association with
PARN. RIP assays were performed as described before, using NEs from HCT116
cells transfected with miR-125b inhibitor expression plasmids or control vectors.
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Figure 39. Functional knockdown of miR-125b inhibits deadenylation of p53
mRNA. A) Deadenylation assays were performed NEs from HCT116 cells
transfected with miR-125b inhibitor expression/control plasmids and a
radiolabeled/polyadenylated RNA encompassing the p53 WT 3’UTR. Positions of
the polyadenylated RNA (p53 3’UTR A20) and deadenylated product (p53
3’UTR) are indicated. Numbers beneath gel lanes indicate relative deadenylation
(RD). RD was calculated as [p53 3’UTR/(p53 3’UTR + p53 3’UTR A20)] x 100.
Quantifications were done with Image J software. B) Regulatory signals at the
3’UTR of p53 are important for deadenylation of p53 mRNA. Deadenylation
assays

were

performed

using

NEs
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HCT116

cells

and

radiolabeled/polyadenylated (A20) RNA encompassing WT or signal replaced
(noARE, nomiR, and noBOTH) 3’UTRs of p53. Deadenylation reactions were
analyzed as in Figure 24.
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DISCUSSION
miRNA pathway was originally believed to act only in the cytoplasm. However, a
growing number of evidence has shown that this pathway has also a nuclear component
(Ohrt et al., 2008). Although it has been shown that nuclear miRISCs are involved in
miRNA-mediated gene silencing in the nucleus (Nishi et al., 2013; Robb et al., 2005), the
mechanism(s) underlying miRNA-mediated regulation of gene expression in the nucleus
remain(s) to be elucidated. Two deadenylase complexes, CAF1/CCR4/NOT1 and Pan2Pan3, have been shown to facilitate cytoplasmic miRNA-mediated deadenylation in
mammalian cells (Behm-Ansmant et al., 2006; Fabian et al., 2009; Piao et al., 2010),
however, little is known about miRNA-mediated deadenylation in the nucleus. Here, my
studies indicate that PARN deadenylase plays a critical role not only in ARE- but also in
miRNA-mediated regulation of mRNA stability and, consequently, expression levels in
the nucleus of mammalian cells. Consistent with this, biochemical evidence shows that
PARN is a nuclear miRISC-associated deadenylase: both PARN and elements of miRISC
were present in the nuclear fractions (Figure 21), PARN physically interacted with Ago2, a key a component of mammalian miRISC complex (Figures 22-23), and Ago-2
activated PARN deadenylase activity (Figures 24-25). Extending these studies, I showed
that PARN regulated the expression of one of its targets, p53, by interacting with not only
ARE sequences but also miRNA targeting sites present in the 3’UTR of p53 mRNA
(Figure 31-33). Furthermore, my results indicate that Ago-2 (Figure 27) and miR125b
(Figure 38) facilitated the binding of PARN to the target p53 mRNA 3’UTR resulting in
p53 mRNA poly(A) tail shortening and decrease in p53 transcript and protein levels.
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Taken together, these results provide new insights into the nuclear function of miRISCs
in the PARN-mediated regulation of deadenylation and gene expression.
Previous work from Dr. Kleiman’s lab showed an alternative mechanism to
regulate the expression levels of p53 based on the control of the steady-state levels of p53
mRNA by PARN deadenylase under non-stress conditions (Devany et al., 2013). Based
on the results presented here, I propose a model in which, under non-stress conditions,
miRISC targets p53 mRNA through miR-125b resulting in the recruitment of PARN
deadenylase by its direct interaction with miRISC major component Ago-2. The binding
of PARN to these protein complexes activates its deadenylation activity resulting in p53
mRNA decay and control of gene expression (Figure 40). The steady-state levels of other
PARN target mRNAs, such as c-myc, c-fos, c-jun, and transcripts in the p53 and
BARD1/BRCA1 pathways, might be regulated following a similar model. Although more
work is necessary to determine the identity of the ARE-BPs involved in PARN-mediated
degradation of p53 mRNA, these results indicate that ARE sequences are also involved in
this process. Most of the known PARN-associated ARE-BPs, such as tristetraprolin
(TTP) and KH-type splicing regulatory protein (KSRP), are involved in the deadenylation
of ARE-containing mRNAs followed by the recruitment of the exosome (Cevher and
Kleiman, 2010).
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Figure 40. Model of multicomponent complexes required for regulation of
p53 mRNA steady-state levels by nuclear PARN deadenylase in different
cellular conditions. Cooperation of ARE-BPs, miRNAs, miRISC, PARN
deadenylase and exosome is essential for the regulation of p53 mRNA stability in
different cellular conditions. The recruitment of the ARE-BPs to the ARE
sequence and/or the targeting of miR-125b-loaded miRISC complexes to the most
proximal site to the ARE sequence assist in the recruitment of PARN deadenylase
to the target mRNA. Changes in the ARE-BPs bound to the 3’UTR, miRNA
abundance and Ago-2 cellular localization might signal the DDR. miRNA
targeting sites present in p53 mRNA 3’UTR are shown in different colors (miR25 gray, miR-30d purple, miR-125b red, miR-504 orange).
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Regulation of mRNA stability by sequences in the UTR of the mRNA is not a
new concept. The typical scenario is the control of mRNA stability by 3’UTR sequences
and the recruiting of diverse protein regulators. The implication of both cis-acting RNA
elements and trans-acting protein factors increases the complexity of the regulation of
gene expression. The studies presented in this dissertation indicate that the presence of
both miRNA binding sites and AREs at the 3’UTR is critical for PARN-dependent
regulation of mRNA deadenylation and stability. However, further studies are necessary
to determine whether the proximity of these regulatory elements is important in this
PARN-associated regulatory pathway. Although the exact contribution of miRNAs,
miRISC, AREs and ARE-BPs to mRNA decay has not been elucidated yet, recent studies
have described a functional overlap between ARE- and miRNA-mediated mRNA
turnover pathways (Zhang et al., 2010). It has been described that miRNAs can
functionally interact with ARE-BPs, and that Dicer and Ago are required for AREmediated decay (Jing et al., 2005). For example, it has been shown that HuR can bind to
AREs present in c-myc 3'UTR at a site proximal to that recognized by let-7 miRNA,
facilitating the targeting of let-7-loaded miRISC and mediating the reduction of c-Myc
mRNA levels (Kim et al., 2009). Another example is the functional interaction of AREBP TTP and miRISC that results in the recruitment of the deadenylase and the exosome
for tumor necrosis factor-α mRNA degradation (Jing et al., 2005). Interestingly, 20% of
PARN mRNA targets in the p53 signaling pathway showed both miRNA target sites and
an ARE in their 3’UTRs (Table 1). Some of my studies work indicates that PARN
regulates the stability of short-lived ARE-containing mRNAs involved in the control of
cell growth, DDR and differentiation, and keeps their levels low (Cevher et al., 2010;
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Devany et al., 2013). PARN deadenylase is recruited to ARE sequences by ARE-BPs
KSRP (Gherzi et al., 2004), CUG-BP (Moraes et al., 2006) or TTP (Korner and Wahle,
1997; Lai et al., 2003). It is possible that miRNA-loaded miRISC might contribute with
one of these ARE-BPs to the recruitment of PARN to its target mRNAs.
The results presented in this dissertation also indicate that Ago-2 shuttles from the
nucleus to the cytoplasmic compartment upon DNA-damaging conditions (Figure 21),
and this might contribute to the UV-induced increase in p53 expression levels. The UVinduced decrease of nuclear Ago-2, which is involved in the recruitment of PARN to p53
mRNA and activation of its deadenylase activity, might explain my observation that the
UV-induced changes in p53 expression are PARN-independent (Devany et al., 2013).
Furthermore, the UV-induced changes in miRNA-expression profiles (Pothof et al.,
2009) might also contribute to the previously described PARN-independent changes in
p53 expression levels (Devany et al., 2013), providing an additional layer of gene
regulation and a new dimension to DDR. The UV-induced changes in the binding of
different ARE-BPs to the 3’UTRs of the PARN target mRNAs might also influence the
resulting expression levels. For example, it has been shown that after UV treatment AREBP Human Antigen R (HuR) binds to AREs, resulting in the dissociation of TTP and
KSRP from ARE-containing mRNAs and the up-regulation of genes involved in DDR
(Cevher and Kleiman, 2010).
Taken together, my characterization of PARN-dependent regulatory pathways
indicates a novel nuclear function of miRISC in controlling gene expression of different
genes in different cellular conditions. The study presented in this dissertation addresses
the mechanism behind miRNA-dependent control of deadenylation in the nucleus,
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showing the functional interplay among PARN deadenylase, the AREs in the 3’UTR,
miRNA abundance and Ago-2 cellular localization. My studies also provide new insights
on regulatory mechanisms in the p53 pathway. While most of the studies on the
expression of genes involved in stress response pathways have traditionally focused on
transcription as a major regulator, it has recently become apparent that the
posttranscriptional control of mRNA steady-state levels may play an equally important
role. The mechanism(s) behind the regulation of p53 mRNA levels under non-stressed as
well as DNA-damaging conditions has(ve) not been well characterized. My results
indicate that PARN deadenylase keeps p53 levels low in non-stress conditions by
interacting with both AREs and miRNA targeting sites in the 3’UTR and destabilizing the
p53 mRNA. Importantly, these studies support the functional overlap between ARE- and
miRNA-mediated mRNA turnover pathways, increasing the complexity of the signaling
present in the 3’UTR of different genes. This is consistent with the idea that cell-specific
3′ processing profiles, and hence gene expression patterns, depends on the complexity of
the signaling in the 3’UTR of the genes and the functional/dynamic interaction of the 3′
processing machinery and the DNA damage response/tumor suppression factors,
providing functional connection between mRNA processing and cancer subtypes, and
proposing new approaches in the design of new cancer therapies.
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CHAPTER V
NUCLEOLIN REGULATES PARN-DEPENDENT DEADENYLATION
IN DIFFERENT CONDITIONS
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INTRODUCTION
Nucleolin is a highly conserved, multifunctional RNA binding protein (RBP)
implicated in several cellular processes, such as chromatin remodeling, rRNA synthesis,
mRNA processing, ribosome assembly, and nucleo-cytoplasmic transport (Angelov et al.,
2006; Ginisty et al., 1998; Hovanessian et al., 2010; Turner et al., 2009). Elevated levels
of nucleolin are found in highly proliferative cells including a variety of tumors.
Nucleolin is primarily located in the nucleolus but it is also found in other nuclear regions
as well as in cytoplasm and plasma membrane (Borer et al., 1989; Ginisty et al., 1999).
Nucleolin has RNA- and p53-binding properties (Serin et al., 1997; Srivastava and
Pollard, 1999; Tajrishi et al., 2011; Tuteja and Tuteja, 1998), and can control gene
expression by regulating mRNA stability and modulating the p53 signaling pathway
(Abdelmohsen and Gorospe, 2012; Abdelmohsen et al., 2011; Bhatt et al., 2012; Chen et
al., 2012; Daniely et al., 2002; Saxena et al., 2006; Takagi et al., 2005; Willimott and
Wagner, 2010). For example, nucleolin modulates gene expression by direct binding to
the untranslated regions (UTRs) of its target mRNAs resulting in a change of mRNA
stability or translation level. Nucleolin can also control gene expression by modulating
the p53 signaling pathway indirectly through protein-protein interactions. For example, it
has been shown that the N-terminus of nucleolin associates with p53-antagonist Hdm2 in
hyperproliferative cells to stabilize p53 protein and causes p53-mediated apoptosis (Bhatt
et al., 2012).
Most of the nucleolin target mRNAs are from stress-responsive genes and from
genes whose expression is affected in disease, such as Alzheimer’s, cancer and
inflammation. Some of nucleolin target mRNAs include antiapoptotic factor bcl-2
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(Ishimaru et al., 2010; Otake et al., 2007; Willimott and Wagner, 2010), amyloid
(Rajagopalan et al., 1998), JNK-mediated interleukin 2 (Chen et al., 2000)

-globin

(Jiang et al., 2006), tumor suppressor p53 (Takagi et al., 2005), potent pro-survival
protein Akt1 (Abdelmohsen et al., 2011), and the growth arrest- and DNA damage
inducible 45 protein (Gadd45α; (Zhang et al., 2006). Most of them bear AU-rich
elements (AREs) or G-rich elements at their UTRs (reviewed by (Abdelmohsen and
Gorospe, 2012). Nucleolin has been demonstrated to either increase or decrease the
stability of the target mRNAs. For example, during DDR, nucleolin can stabilize the
antiapoptotic mRNA bcl-XL by interacting with the AREs in their 3’UTR and protecting
the poly(A) tail by association with poly(A) binding protein (PABP; (Zhang et al., 2008)
and inhibit p53 mRNA translation by interacting with the 5’UTR (Chen et al., 2012;
Takagi et al., 2005). Recently, transcriptome-wide analyses revealed that nucleolin
enhances translation of mRNA with G-rich motif (Abdelmohsen et al., 2011).
Interestingly, nucleolin’s expression, subcellular localization and post-translational
modification are linked to its role as an RNA-binding stress responsive protein (Aoki et
al., 2002; Daniely et al., 2002; Ginisty et al., 1998; Gorospe et al., 2011; Grinstein and
Wernet, 2007; Kim et al., 2005; Masuda et al., 2009; Rickards et al., 2007). Therefore, it
has been suggested a role for nucleolin in the regulation of mRNA stability of different
target genes upon DNA damage, providing multiple levels of differential regulation of
gene expression:
It has been shown that nucleolin binds to p53 mRNA at a 5’UTR and 3’UTR
base-pairing region in unstressed cells resulting in the repression of p53 mRNA
translation (Chen et al., 2012). After DNA damage and stress stimulation, RPL26 is
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recruited to this double-stranded RNA structure occupied by nucleolin forming nucleolinRPL26 heterodimers and enhancing the translation of p53 mRNA. However, whether
nucleolin associates with AREs present in the 3’UTR of p53 mRNA and affects p53
mRNA stability has not been tested. A recent report has shown that nucleolin mediates
microRNA (miRNA)-directed deadenylation of the colony stimulating factor-1 (CSF-1)
mRNA by binding factors from the miRNA-induced silencing complex (miRISC), such
as Argonaute-2 (Ago-2) and cytoplasmic poly(A) binding protein 1 (PABPC-1) (Woo et
al., 2013). Interestingly, the nucleolin/Ago2/PABPC-1 complex formation requires ARE
regulatory elements present on the CSF-1 mRNA 3’UTR, supporting the functional
interplay between miRNA- and ARE-mediated regulation of mRNA stability discussed in
Chapter IV.
Nucleolin can be phosphorylated by numerous kinases. Changes in the
phosphorylation of nucleolin play a role in several critical cellular processes, such as cell
growth, proliferation, cell cycle arrest, apoptosis as well as DNA damage response
(DDR) (Daniely et al., 2002; De et al., 2006; Ishimaru et al., 2010; Kim et al., 2005;
Nalabothula et al., 2010; Saxena et al., 2006; Storck et al., 2007; Takagi et al., 2005;
Yang et al., 2009; Yang et al., 2002). Nucleolin is highly phosphorylated at the Nterminus by two major kinases: interphase casein kinase II (CKII) and mitotic cyclindependent kinase (Cdk/Cdc2) (Schneider et al., 1986; Warrener and Petryshyn, 1991).
CKII-mediated phosphorylation of several cytosolic and nuclear substrates, including
nucleolin, appears to be important for the regulation of cell growth. The extensive
phosphorylation of nucleolin by CKII that occurs during interphase suggests that
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phosphorylation may be a mechanism for regulating nucleolin function during the cell
cycle.
Nucleolin has distinct domains: the acidic N-terminus, which is highly
phosphorylated by CKII and Cdks and contains the bipartite nuclear localization signal
(NLS); four central RNA binding Domains (RBDs) that confer RNA-binding specificity,
and the C-terminal Glycine-Arginine Rich (GAR) domain that exhibits helicase activity
and is involved in many protein interactions including PABP and p53 (Figure 43; Tuteja
and Tuteja, 1998; Ginisty et al., 1999; Srivastava and Pollard, 1999; Daniely et al., 2002;
(Bhatt et al., 2012; Daniely et al., 2002; Ginisty et al., 1999; Srivastava and Pollard,
1999; Tuteja and Tuteja, 1998; Zhang et al., 2008). Our collaborator, Dr. Saxena
(Brooklyn College, CUNY), has engineered a novel system with tet-off promoter in
human NARF6 cells to express 3xFlag-tagged WT-nucleolin or the phospho-variant
6/S*A-nucleolin. In the phospho-variant nucleolin, six consensus CK2 phosphorylation
sites were mutated from serine to alanine (Figure 41). The Tet-off promoter system
allows nucleolin variants expression after removal of doxycycline (Dx) from the culture
medium. The 6/S*A-nucleolin was tested deficient in phosphorylation by Dr. Saxena Lab
(unpublished data kindly provided by Dr. Saxena). They also showed that although both
phospho-variants of nucleolin increase p53 protein levels in unstressed cells, a greater
increase in p53 is evident with 6/S*A expression. Interestingly, 6/S*A expression inhibits
cell proliferation, probably due to increased p53 levels (Dr. Saxena personal
communication). These differential effects on p53 induction and cell proliferation suggest
a role for nucleolin phosphorylation in regulating gene expression of different target

103

genes in the p53 pathway. Thus, these inducible cell lines are valuable tools to facilitate
studies and testing the role of nucleolin in gene regulation during the DDR.

Figure 41. Modular structure of Nucleolin protein (WT and 6/S*A),
indicating the positions of principal domains. The six consensus CK2 sites
(serine residues) mutated to alanine in phospho-mutant construct-6/S*A are
denoted by asterisks.

Based on these studies, in this chapter I propose to dissect nucleolin’s role in
governing mRNA stability of diverse target genes involved in DDR, and also provide
mechanistic insights about the role of nucleolin phosphorylation in DDR. The specific
hypothesis is that nucleolin interacts with mRNA 3’ processing factors and regulates the
mRNA stability of genes involved either in the DNA repair or apoptotic response during
the DDR. The working model is that nucleolin regulates stability of ARE-containing
mRNAs by recruiting PARN deadenylase into its target mRNAs, such as p53 mRNA,
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and these functions are modified by nucleolin phosphorylation state. Preliminary studies
from Dr. Saxena’s lab indicate that cells expressing 6/S*A-nucleolin show increased
levels of p53 expression in non-stress conditions, suggesting that the expression of this
nucleolin

phospho-variant

mimics

stress

conditions.

They also

showed that

nucleolin/PARN interaction increases after UV treatment, and this increase is abolished
in samples expressing the nucleolin phospho-variant (not shown). Interestingly, my
studies show that both nucleolin-WT and 6/S*A can interact directly with N-terminal
domain of PARN in in vitro assays. The expression of WT nucleolin is necessary for the
UV-induced activation of deadenylation, and this activation is abolished by the
expression of 6/S*A nucleolin, suggesting that active dephosphorylation of nucleolin
might be necessary for the activation of PARN deadenylation during DDR. Nucleolin
interacts with the 3’UTR of one of PARN substrates, the p53 mRNA, under non-stress
conditions in an AU-rich element (ARE)-dependent manner. Nucleolin phosphorylation
affects its association with p53 mRNA both before and after UV treatment. Together
these results indicate that the functional interaction of nucleolin with PARN deadenylase
might provide a molecular mechanism for the rapid response to DNA damage allowing
changes in the stability of different mRNAs, and this response might be regulated by
nucleolin phosphorylation.
RESULTS
Preliminary data from Dr. Saxena’s lab showed that nucleolin/PARN interaction
increases after UV treatment, and this increase is abolished in samples expressing the
nucleolin phospho-variant (not shown). Extending those studies, I first tested whether
nucleolin interacts directly with PARN. Pull-down assays were performed using both
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Flag-tagged nucleolin phospho-variants purified from NARF6 cells and different HisPARN derivatives (Figure 42). The results indicated that PARN can interact directly with
both WT- and 6/S*A-nucleolin, and that the N-terminal domain, which contains the
nuclease activity and is responsible for cap-binding properties of PARN (Martinez et al.,
2001), is important for this interaction (Figure 42). Together these results indicate that
both nucleolin phospho-variants can interact with the N-terminal domain of PARN. This
suggests that the decrease in the UV-induced formation of the nucleolin/PARN complex
in cells expressing 6/S*A variant observed by Dr. Saxena’s lab might be due the need of
active dephosphorylation or other factors for the complex formation.
B
Pull-down
Input
WT
Nucleolin-

6/S*A
Nucleolin-

% NCL PD by His-PARN

A

12
10
8
6
4
2
0

His-PARN:
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NTD
WT
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NTD
6/S*A

Figure 42. Nucleolin directly interacts with N-terminal domain of PARN.
Different His-PARN derivatives (FL: full-length, CTD: carboxyl-terminal
domain, NTD: amino-terminal domain) were immobilized on nickel beads and
incubated with WT or 6/S*A mutant nucleolin. Bound proteins were eluted,
resolved by SDS-PAGE and detected with anti-nucleolin antibodies. 5% of Flagtagged nucleolin is shown as input.
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To test the role of nucleolin in PARN-mediated deadenylation, in vitro
reconstituted deadenylation assays were performed using radiolabeled L3(A 30) RNA
substrate to monitor the reaction, limiting amounts of recombinant His-PARN and
increasing amounts of either WT-nucleolin or 6/S*A-nucleolin. As previously shown,
increasing amounts of PARN deadenylase resulted in an increase of RNA substrate
deadenylation (Figure 43, lanes 2-5). Importantly, only increasing amounts of purified
Flag-tagged WT nucleolin can induce deadenylation in a reaction using a limited amount

Flag-Nucleolin:
His-PARN:

-

-

-

-

0.75 1.5

-

3

7.5

Flag-6/S*A

Flag-WT

0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 ng

-L3A30

-L3
Relative
Deadenylation:

8.1

11.2

22.5

28.2

37.5 12.3 14.5

15.7

13.5 27.7 35.6

45.9 58.3

Figure 43. WT-nucleolin but not the 6/S*A phospho-variant activates PARN
deadenylase activity. Deadenylation assays were performed in the presence of
radiolabeled capped L3(A30) RNA substrate as described (Cevher et al., 2010)
using different concentrations of His-PARN and increasing amounts of either
Flag-WT-NCL or Flag-6/S*A-NCL. Positions of the polyadenylated RNA
L3(A30) and the L3 deadenylated product are indicated. Numbers beneath gel lane
indicate

relative

deadenylation

(RD),

which

was

calculated

as

[L3

fragment/(L3(A30) + L3 fragment)] x 100. Quantifications were done with Image
J software.
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of His-PARN in a cell-free assay, suggesting that this is a transactivation-independent
function of nucleolin. PARN-mediated deadenylation was enhanced up to 5.2 folds in the
presence of WT-nucleolin (compare lane 2 and lane 10-13). The addition of Flag-tagged
6/S*A-nucleolin did not have an effect on the deadenylation reaction (lanes 6-9). None of
the phosphor-varinats were able to deadenylate the substrate in the absence of His-PARN
(not shown). These results suggested that nucleolin is an activator of PARN deadenylase
activity and nucleolin phosphorylation is necessary for this activation.
Extending these studies, the role of nucleolin in deadenylation was tested using
nuclear extracts (NEs) from cells expressing nucleolin-variants treated with either UV
irradiation or Isopropyl β-D-1-thiogalactopyranoside (IPTG) to induce ARF/p53
expression. NEs from those cells were assayed for deadenylation activity using a
radiolabeled L3(A 30) RNA substrate. As described in previous studies (Cevher and
Kleiman, 2010; Devany et al., 2013), Figure 44A shows that deadenylation activity in
NEs of cells expressing WT-nucleolin increased significantly (up to 3.3 folds) after UV
treatment (compare lanes 2 and 3). Interestingly, UV-induced activation of deadenylation
was abolished in samples from cells expressing 6/S*A-nucleolin (compare lanes 5 and 6).
As cells expressing 6/S*A-nucleolin show increased expression of p53 in non-stress
conditions (information kindly provided by Dr. Saxena’s) and previous studies from Dr.
Kleiman’s lab showed that p53 is an activator of PARN deadenylase activity (Devany et
al., 2013), I decided to test whether p53 expression is sufficient to activate deadenylation.
Interestingly, the IPTG-induced expression of p53 enhanced deadenylation to a similar
level to that observed in samples from cells expressing WT-nucleolin treated with UV
irradiation (compare lanes 1 to 3). These results suggest that deadenylation can be
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activated by the induction of p53 expression in either DNA damage or oncogenic stimuli
conditions. Importantly, IPTG treatment induced deadenylation in samples from cells
expressing 6/S*A– nucleolin (compare lanes 1 to 4). Together, these results indicate that
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IPTG (p14ARF):
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Deadenylation: 16.5
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Figure 44. Nucleolin phosphorylation is necessary for deadenylation
activation upon UV-induced but not in the oncogenic stimuli. A) NEs prepared
from cells expressing nucleolin phospho-variants treated with/without UV
irradiation (40 Jm-2) were prepared 2 h post-treatment and analyzed for
deadenylation. Alternatively, cells were treated with 1.5 mM IPTG for 24 h to
induce ARF/p53 expression. Positions of the polyadenylated RNA L3(A30) and
the L3 deadenylated product are indicated. Numbers beneath gel lane indicate
relative

deadenylation:

[L3

fragment/(L3(A30)+

L3

fragment)]

x

100.

Quantifications were done with Image J software. B) The bar graph shows the
ratio of deadenylation in UV- or IPTG-treated cells relative to non-stress
conditions.
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nucleolin phosphorylation is necessary for deadenylation activation upon UV-induced
DNA damage but not in the oncogenic stimuli (Figure 44B), suggesting that (a)
mechanism(s) other than p53-induced activation of the deadenylation is involved in this
response.
My results indicate that the RNA binding protein nucleolin binds directly to
PARN deadenylase resulting in the activation of its activity. To further analyze whether
nucleolin plays a role in PARN-mediated regulation of mRNA stability I first tested the
binding of nucleolin to one of PARN mRNA targets, the p53 mRNA (Devany et al.,
2013). The binding of nucleolin to the p53 mRNA was determined by RNA
immunoprecipitation (RIP) assays using antibodies against nucleolin. RIP assays showed
that p53 mRNA can form a complex with nucleolin under non-stress conditions in
samples from cross-linked HeLa cells (Figure 45A), suggesting that nucleolin might
regulate p53 mRNA stability by its association to PARN deadenylase and the 3’UTR of
p53. This result is consistent with a model proposed by a recent report that nucleolin
homodimer binds to p53 mRNA in unstressed cells resulting in the repression p53
translation; while RPL26 disrupts the nucleolin homodimer and forms nucleolin-PRL26
heterodimers resulting in p53 induction after DNA damage, (Chen et al., 2012). As
nucleolin has been shown to associate with its target mRNAs through ARE regulatory
elements in the 3’UTR (Sengupta et al., 2004) and miR targeting sequences (Woo et al.,
2013), I tested whether these cis-acting elements present in the p53 3’UTR are also
important for nucleolin association with the mRNA. RNA pull-down assays were
performed using with in vitro transcribed biotinylated RNAs, either with sequences of the
p53 3′UTR or ARE/miRNA-replaced p53 3′ UTR, and NEs from RKO cells. RNA-pull
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Figure 45. Nucleolin interacts with the 3’UTR of p53 mRNA under non-stress
conditions in an ARE-dependent manner. A) Nucleolin can interact with
endogenous p53 mRNA under non-stress conditions. HeLa cells were treated with
formaldehyde to generate protein-RNA cross-links, then the samples were sheared
by sonication followed by incubation with either anti-nucleolin or IgG antibodies.
The endogenous nuclear RNA immunoprecipitated with the antibodies was
quantified by qRT-PCR using primers specific for p53 gene. The qRT-PCR
values were calculated from three independent samples. Input indicates samples
before RIP. B) Nucleolin interacts with the p53 3’UTR in an ARE-dependent
manner. RNA-pull down assays were performed using NEs from RKO cells and
biotinylated RNA of either p53 or p53 mutant 3’UTRs [no-ARE: AU-rich
element replaced; no-miR: miR504/miR125-b targeting sites replaced].

down assays showed that the replacement of an ARE regulatory sequence in the p53
3’UTR abolished nucleolin binding to p53 mRNA (Figure 45B). Interestingly, the
replacement of miR-504/miR-125b targeting site also decreased the nucleolin’s
association to the p53 mRNA. Together, these data indicates that nucleolin interacts with
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the 3’UTR of p53 mRNA under non-stress conditions and that the presence of the cisacting regulatory sequences ARE and miR-504/miR-125b targeting sites at the 3’UTR of
p53 mRNA are important for the RNA-nucleolin interaction. Interestingly, I showed in
Chapter IV that PARN regulates the stability of p53 mRNA by interacting with not only
ARE sequences but also miR-504/miR-125b targeting sites present in the 3’UTR of p53
mRNA (Figures 32-33), supporting the idea that nucleolin and PARN functional
interaction over the regulation of p53 mRNA stability under non-stress conditions.
Next, I tested whether phosphorylation of nucleolin affect its association with p53
mRNA. RIP assays were performed using Flag antibodies and samples from NARF cells
expressing different phospho-variants of nucleolin treated with or without UV irradiation.
RIP assays showed that (Figure 46). Upon UV-induced DNA damage, both WT- and
6/S*A-nucleolin showed an increase in their association with p53 mRNA. However, p53
mRNA showed stronger interaction with WT-nucleolin than with the 6/S*A-nucleolin
phospho-variant, indicating that nucleolin phosphorylation affects nucleolin association
with p53 mRNA.
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Figure 46. Nucleolin phosphorylation affects its association to p53 mRNA. A)
RIP assays of samples from NARF cells expressing the WT or 6/S*A nucleolin
phospho-variants were performed as before using anti-Flag antibodies. The
nuclear RNA in immunoprecipitated was quantified by qRT-PCR using primers
specific for p53 gene. B) The bar graph shows the ratio of the fold change for UVtreated/non-stress RNA values in nucleolin phospho-variants.

DISCUSSION
The post-transcriptional fate of mRNAs could be affected by many factors. RNA
binding proteins are believed to play a fundamental role in the recognition of mRNA
transcripts and regulating the recruitment of other trans-acting factors and/or factors that
modulate the poly(A) tail, such as deadenylases and poly(A) binding proteins. The
specific sequences that any RNA binding protein recognizes on its target transcripts and
the location relative to other elements are of vital importance for regulation of gene
expression. Diverse mRNA isoforms carrying different arrangement of regulatory signals
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can be generated and dramatically alter mRNA stability and/or translation, hence gene
expression. The RNA binding protein nucleolin has been shown to recognize the ARE
signal at the 3’UTR of several mRNA targets and regulate their stability (Sengupta et al.,
2004). However, whether nucleolin plays a role in modulating p53 mRNA steady-state
levels through its ARE element has not been tested. Previous studies have shown that
PARN deadenylase is recruited to the p53 mRNA under non-stress conditions (Devany et
al., 2013), however, the RNA-binding protein(s) necessary to recruit the active
deadenylase to its mRNA substrates leading to mRNA deadenylation and degradation
was not identified. Here my studies indicate that nucleolin binds the N-terminal domain
of PARN deadenylase (Figure 42) and both of them bind to the same ARE element
present in the p53 3’UTR (Figure 45; (Devany et al., 2013)). The PARN/nucleolin
interaction resulted in the activation of PARN deadenylase activity (Figures 43-44). The
results also indicate that the phosphorylation state of nucleolin is critical for the
PARN/nucleolin functional interaction (Figures 43-44) and for nucleolin binding to p53
mRNA (Figure 46). Together these results indicate that nucleolin is one of the RNA
binding proteins that recruit PARN deadenylase to the tumor suppressor p53 mRNA,
representing a novel regulatory mechanism for p53 gene expression.
While most of the studies on the expression of genes involved in stress response
pathways have traditionally focused on transcription as a major regulator, it has recently
become apparent that the posttranscriptional control of mRNA steady-state levels may
play an equally important role. The mechanism(s) behind the regulation of p53 mRNA
levels under non-stressed as well as DNA-damaging conditions has(ve) not been well
characterized. The results presented here indicate that nucleolin recruits PARN
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deadenylase to p53 mRNA keeping p53 levels low in non-stress conditions by interacting
with AREs in the 3’UTR and destabilizing the p53 mRNA. It is possible that a similar
mechanism is used to regulate the steady-state levels of other mRNAs, hence gene
expression, in different conditions. Nucleolin has been implicated in many different
cellular processes through the identification of its target transcripts. It has been shown
that nucleolin participates in the control of the steady-state levels of ARE-containing
mRNA targets by regulating their stability and translation. It has been shown that
nucleolin is involved in the stabilization of bcl2 mRNA through its association with an
ARE signal present in the 3’UTR of bcl2 transcript resulting in an increase of its
expression (Sengupta et al., 2004). Another target of nucleolin is bcl-XL mRNA, which
is stabilized by nucleolin association to its ARE in response to UVA irradiation (Zhang et
al., 2008). However, nucleolin also contributes to the selective destabilization of some
other mRNA targets. For example, nucleolin associates with the 3’UTR of amyloid
precursor protein (APP) mRNA and enhances its degradation in response to stress
(Westmark and Malter, 2001). Consistent with this, other ARE-BPs have also been
shown to increase and decrease mRNA stability in a gene-specific manner. For example,
HuR-elicited stabilization of target mRNA has been extensively documented:
stabilization of ARE-containing mRNAs during UV irradiation (Wang et al., 2000), heat
shock (Gallouzi et al., 2000), hypoxia (Levy et al., 1998) and energy depletion (Jeyaraj et
al., 2005). HuR has also been shown to recruit miRNA-induced silencing complex
(miRISC) miRISC to destabilize c-myc mRNA and repress its expression (Kim et al.,
2009).
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It is a widespread strategy to regulate ARE-mediated mRNA decay by changing
the phosphorylation state of RNA binding proteins resulting in changes in their ability to
bind their target mRNAs. For example, the phosphorylation of tristetraprolin (TTP) by
MAPKAP kinase 2 (MK2) reduces binding affinity of TTP for its target mRNA, such as
tumor necrosis factor-α (TNF-α), Granulocyte-macrophage colony-stimulating factor
(GM-CSF) and interleukin 2 (IL-2) (Chrestensen et al., 2004). The p38 pathwaymediated phosphorylation of KSRP reduces its association to the ARE region at the
3’UTR leading to the stabilization of its mRNA targets (Briata et al., 2005). On the
contrary, HuR phosphorylation enhances its binding to target mRNAs (Lafarga et al.,
2009). Interestingly, consistent with the results shown in Figure 46, it has been reported
that the RNA-binding activity of nucleolin is also affected by phosphorylation. Nucleolin
is phosphorylated in response to DNA damage by stress-activated protein kinases
(SAPK) p38, and this increases its association with a subset of stress responsive

transcripts in a UV irradiation dose-dependent manner (Yang et al., 2002). The results
presented here indicate that cells expressing the dephospho-variant of nucleolin show a
decrease in nucleolin binding to p53 mRNA (Figure 46) and in PARN deadenylase
activity (Figures 43-44), which might probably result in an increase in p53 mRNA levels
and explain the increase in p53 protein expression observed by Dr. Saxena’s lab (personal
communication).
Interestingly, Woo et al. (2013) recently described a role for nucleolin in miRNAdirected mRNA deadenylation. Nucleolin interacts with the miRISC component Ago2
indirectly via RNA and induces deadenylation of CSF-1 mRNA. Interestingly,
nucleolin/Ago2-mediated degradation of CSF-1 mRNA depends on the functional
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overlapping of miRNA targeting sites and AREs located at the 3’UTR of the target
transcript (Woo et al., 2013). The results shown in this dissertation also indicate that both
ARE sequences and miR targeting sites are involved in nucleolin binding to the p53
mRNA (Figure 45), suggesting that nucleolin might regulate mRNA deadenylation of
different targets through a similar mechanism. Surprisingly, the studies presented in
Chapter IV indicate that PARN can interact directly with Ago2 (Figure 23) and that
regulates the stability of p53 mRNA by interacting with not only ARE sequences but also
miR-504/miR-125b targeting sites present in the 3’UTR of p53 mRNA (Figures 32-33).
Furthermore, my results indicate that Ago-2 (Figures 27 and 32) and miR-125b (Figure
38) facilitated the binding of PARN to the target p53 mRNA 3’UTR resulting in p53
mRNA poly(A) tail shortening and decrease in p53 transcript and protein levels. Further
work is necessary to investigate whether the phosphorylation state of nucleolin, which is
important for the activation of PARN deadenylase and association to p53 mRNA, has an
effect on p53 mRNA decay under different cellular conditions.
Together, these studies suggest a functional interplay among PARN deadenylase,
the RNA binding protein nucleolin, ARE elements, miRNA targeting sites, miRNAloaded miRISC, and miRNA abundance; and address the molecular mechanism behind
miRNA-mediated/ARE-directed deadenylation of p53 mRNA in the nucleus. The model
proposed in this work also provides a molecular mechanism for the rapid response to
DNA damage allowing changes in the stability of different mRNAs by regulating
nucleolin phosphorylation.
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CHAPTER VI
FUTURE DIRECTIONS
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The modulation of mRNA stability plays important roles in the regulation of gene
expression. Many mechanisms and factors are implicated in this precise control of
mRNA turnover, which is more complex than it was previously thought. PARN
deadenylase is one of the important factors involved in these regulatory pathways. PARN
has been involved in several important biological processes, such as oocyte maturation,
early development, DNA damage response (DDR) and cell-cycle progression. The results
presented in this dissertation indicate that PARN deadenylase is involved in an alternative
mechanism to regulate of p53 expression levels under non-stress conditions. Moreover,
my studies also show that the functional interaction of PARN with microRNA (miRNA)induced silencing complex contributes to the regulation of the stability of p53 mRNA
(Figures 35-38). This data is innovative because it is the first description of PARN
deadenylase function in miRNA-dependent control of mRNA decay. Importantly, this is
also the first mechanistic report of miRNA-function in the nucleus, which has been
traditionally believed to take place only in the cytoplasm.
Previous studies have shown that PARN is implicated in AU-rich elements
(ARE)-mediated deadenylation and that several ARE-binding proteins facilitate PARN
access to its targets, ARE-containing mRNAs, resulting in PARN dependent
deadenylation. In this dissertation, these studies have been extended showing that PARN
deadenylase has a specific effect on the steady-state levels of mRNAs containing not only
AREs but also miRNA target sites (Figures 10, 12-13, Table 1). More importantly, I
found that miR-125b-loaded miRNA-induced silencing complex (miRISC) contributes to
the specific recruitment of nuclear PARN to one of its targets, the tumor suppressor p53
mRNA (Figure 38), and ARE-binding protein nucleolin associates to the ARE element
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that overlaps miR-125b target site and regulates PARN deadenylase activity (Figures 4548), representing a novel regulatory mechanism for p53 gene expression.
The studies presented in this dissertation are innovative because they are the first
to address the mechanism behind miRNA-dependent control of deadenylation in the
nucleus and the functional interplay among PARN deadenylase, the regulatory signals in
the p53 3’UTR, ARE-binding proteins, miRNA abundance and Ago-2 cellular
localization. Now, it is important to further elucidate the complete mechanism behind
PARN-mediated regulation of its targets in different cellular responses. The following
proposed studies might help to understand some aspects of the working model shown in
this dissertation.
1) Further characterization of the role of PARN deadenylase in the regulation of
mRNA stability of genes containing overlapped AREs and miRNA target sites:
In recent years, the mechanisms underlying the miRNA-mediated repression of
target mRNAs have been extensively explored. miRISCs, which deliver miRNAs to their
mRNA targets, regulate gene expression through post-transcriptional events either by
mRNA degradation, translation inhibition, or a combination of both. In this dissertation,
it has been shown that Ago-2, the core component of the miRISCs, interacts directly and
can coexist in complexes with PARN resulting in the activation of its deadenyase activity
(Figures 22-25), supporting the idea that Ago-2 is critical for miRNA-mediated poly(A)
removal. It is known that Ago-2 associates to the other miRISCs components, such as the
GW182 factor and cytoplasmic poly(A) binding protein 1 (PABPC1), that contribute to
miRNA-directed deadenylation (Fabian et al., 2009; Jinek et al., 2010; Zekri et al., 2009).
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GW182 protein is considered the link between miRISCs and deadenylases, and it is
important for promoting poly(A) removal (Lazzaretti et al., 2009; Takimoto et al., 2009;
Zipprich et al., 2009). The other critical component of the miRISC, PABPC1, has a
bimodal effect on PARN deadenylase activity: it can either activate or inhibit PARN
deadenylase depending on the salt concentration (Korner and Wahle, 1997). Interestingly,
PABPC1 has been traditionally considered to localize only in the cytoplasmic
compartment. However, recent studies have revealed a role of PABPC1 during mRNA
biogenesis in the nucleus (Lemay et al., 2010). It is also possible that the nuclear poly(A)
binding protein (PABPN) might be the one associated with nuclear miRISCs and
involved in recruiting PARN to the poly(A) tail and allowing miRNA-mediated
deadenylation. Whether GW182 and/or PABC1 associates with PARN and affects its
deadenylase activity remains to be determined.

Therefore, the elucidation of the

functional interactions between PARN and these factors involved might provide a
dynamic picture of the molecular networks used to regulate gene expression in different
cellular conditions. It is important to highlight that Ago-2 binds directly PARN
deadenylase and that is sufficient to recruit PARN to its target mRNAs (Figures 23, 27,
32), suggesting that PARN interaction with any of the other components of the miRISc
might be regulatory.
The results presented in this dissertation indicate that PARN regulates the stability
of short-lived ARE-containing mRNAs implicated in the control of cell growth, DDR and
differentiation, and keeps their levels low in non-stress conditions (Cevher et al., 2010;
Devany et al., 2013). Interestingly, it has been shown that PARN deadenylase is recruited
to ARE sequences by ARE-binding protein KH-type splicing regulatory protein
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(KHSRP) (Gherzi et al., 2004), CUG binding protein (CUG-BP; (Moraes et al., 2006) or
tristetraprolin (TTP; (Korner and Wahle, 1997; Lai et al., 2003). In this study, the
possible role of RNA binding protein nucleolin in the PARN-mediated regulation of p53
expression was examined. The data presented in this dissertation showed that nucleolin
associates with p53 mRNA through an ARE element at the 3’ untranslated region
(3’UTR), and its phosphorylation state affects both nucleolin targeting to p53 mRNA and
PARN-dependent deadenylation (Figures 43-46). However, whether nucleolin and its
phosphorylation state play a role in facilitating PARN recruitment to the target mRNA
and promoting p53 mRNA degradation under non-stress conditions need to be further
elucidated. It is also important to determine how nucleolin functional interaction with
PARN changes during the DDR. It would be also important to study the possible
regulatory effect on PARN deadenylase of other ARE-binding proteins, such as HuR and
Wig-1, that have been shown to bind the p53 3’UTR at an ARE signal proximal to miR125b targeting site.
Although the exact contribution of miRNAs, miRISC, AREs and ARE-BPs to
mRNA decay has not been elucidated yet, recent studies have revealed a functional
overlap between ARE- and miRNA-mediated mRNA turnover regulatory pathways
(Zhang et al., 2010). For example, it has been shown that the functional interaction of
ARE-binding protein TTP and miR-16-loaded miRISC results in the recruitment of the
deadenylase and the exosome to tumor necrosis factor-α mRNA resulting in its
degradation (Jing et al., 2005). Another example is the binding of HuR to AREs present
in c-myc 3'UTR at a site proximal to that recognized by let-7 miRNA, facilitating the
targeting of miRISC and mediating the reduction of c-myc mRNA levels (Kim et al.,
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2009). The studies presented in this dissertation indicate that 20% of PARN mRNA
targets in the p53 signaling pathway showed both miRNA target sites and an ARE in
their 3’UTRs (Table 1). It has also been shown that the presence of both miRNA binding
sites and AREs at the 3’UTR is critical for PARN-dependent regulation of mRNA
deadenylation and stability (Figures 30-33 and 39).

However, further studies are

necessary to determine whether the proximity of these regulatory elements is important in
this PARN-associated regulatory pathway.
2) Characterization of the role of mRNA 3’ processing in regulating p53 mRNA
expression during DDR:
p53 is an important tumor suppressor which is implicated in various cellular
processes by regulating the expression of a large number of genes involved in DNA
repair, cell cycle arrest, and apoptosis through transcription activation. Besides its well
established role as a transcriptional regulator, p53 has also been described to have
transactivation-independent functions, such as mediating expression of certain miRNAs
(reviewed in (Takwi and Li, 2009) and regulating mRNA 3’ processing (Devany et al.,
2013). It is the most commonly mutated gene in human tumors, and the regulation of p53
levels under different cellular conditions is critical. It is well established that in response
to cellular stress signals, p53 protein accumulates as a result of the downregulation of
Mdm2 levels, which acts as an E3 ligase targeting p53 for degradation under non-stress
conditions.
The results presented in this dissertation showed that p53 and p53 signaling
pathway are specific targets of PARN deadenylase under non-stress conditions. However,
after UV-induced DNA damage, the changes in both p53 mRNA and protein levels are
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PARN independent (Figure 14), suggesting that other mechanisms are involved in the
regulation of p53 expression during DDR. Interestingly, data presented in this
dissertation indicate that after UV irradiation Ago-2 translocates to cytoplasm and the
abundance of p53 mRNA targeting miRNAs decreases, such as miR-125b and miR-504
(Figures 21 and 34). These observations suggest that when cells are under stressed
conditions, changes in Ago-2 cellular localization and miRNA abundance might signal
the DDR, leading to PARN dissociation from p53 mRNA. Since the regulation of p53
expression in non-stress conditions requires the cooperation of miRISCs, ARE-binding
proteins and PARN deadenylase, an intriguing possibility could be that the dynamic
change in the interaction of different factors with the same region of p53 3’UTR results
in the stabilization of p53 mRNA, leading to the p53 induction in response to DNA
damage.
HuR, an ubiquitously expressed ARE-binding protein that belongs to the Hu
(ELAV) family, has been shown to bind an ARE element at p53 mRNA 3’UTR and
increase p53 mRNA stability after stress (Zou et al., 2006). Importantly, a recent study
described a combinatorial regulation of mRNA stability by HuR and miRNAs
(Mukherjee et al., 2011). In that study it was shown that over 75% of mRNAs with
miRNA binding sites also have HuR binding sites, and most of these signals are less than
10 nt distance from each other. HuR has been shown to be involved in miRNA-mediated
regulation of mRNAs stability by either a competitive or cooperative function. For
example, it has been shown that HuR plays a role in recruiting let-7-loaded miRISC to
repress c-myc expression (Kim et al., 2009). On the other hand, it has also been shown
that upon stress conditions HuR can outcompete and relieve CAT-1 mRNA from miR-
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122-induced repression, leading to the stabilization of the mRNA in human liver cells
(Bhattacharyya et al., 2006). As HuR recognizes the ARE sequence that overlaps with
miR-125b targeting site in p53 mRNA upon DNA-damaging conditions, it is important to
further investigate the potential functional overlapping of PARN/nucleolin-mediated
inhibition of p53 expression under non-stress conditions and HuR-mediated induction of
p53 expression upon DNA damage response.
3) Determination of the mechanisms behind the PARN-mediated regulation of the
steady-state levels of other target genes:
PARN is one of the major mammalian deadenylases and is associated with a
variety of important cellular processes through mediating the deadenylation of a specific
subset of mRNAs. The data presented in this dissertation indicate that the mRNA levels
of both housekeeping genes and ARE-containing genes are regulated by PARN
deadenylase under different cellular conditions (Figure 10). As the tumor suppressors
BARD1 (Cevher et al., 2010) and p53 (Devany et al., 2013) can activate PARN
deadenylase, it is possible that malignant cells display altered levels of polyadenylation
of specific mRNAs. In fact, increased expression of PARN has been detected in acute
lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML; (Maragozidis et al.,
2012), suggesting that the alteration of PARN deadenylase expression might be used as a
potential biomarker for cancer cells. It has been shown that PARN is involved in the
regulation of the stability of several cancer-related mRNAs, such as IL-8, Vascular
endothelial growth factor (VEGF), c-myc, c-fos, c-jun, urokinase-type plasminogen
activator (uPA) and TNF-α (Chou et al., 2006; Lai et al., 2003; Moraes et al., 2006;
Suswam et al., 2008). This is consistent with the microarray results presented here: the
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most affected genes by PARN depletion are p53-related genes that have been shown
linked with cancerous growth and DNA repair activities. Interestingly, 20% of these
PARN mRNA targets in the p53 signaling pathway showed both miRNA target sites and
ARE in their 3’UTRs. The studies presented in this dissertation were carried out using
p53 mRNA as a model to investigate the mechanism underlying PARN-dependent
regulation of mRNA stability. Interestingly, like p53, both fos and myc mRNAs have
proximal AREs and miRNAs targeting sites in their 3’UTRs. Besides the increase in cfos and c-myc mRNA levels in PARN-depleted cells in non-stress conditions were
confirmed by qRT-PCR (Figures 10 and 13). More importantly, functional overlap
between ARE-and miRNA-mediated regulatory pathways has been described to regulate
c-myc mRNA stability and translation levels (Kim et al., 2009). As mentioned before, cmyc expression is repressed by both miRNA let-7 and ARE-binding protein HuR, which
binds to ARE present in c-myc 3'UTR at a site proximal to that recognized by let-7
miRNA (Kim et al., 2009). However, whether PARN is the deadenylase mediating c-myc
mRNA reduction through association with either let-7-loaded miRISC or HuR is not
known. Together, these studies and the results presented in this dissertation suggest a
possible role of PARN in regulating genes containing a conserved arrangement of signals
in their 3’UTR, a miRNA targeting site overlapping or in close proximity to ARE
regulatory signal. Together, future studies designed to test this hypothesis and the studies
presented in this dissertation will serve as a valuable framework both for understanding
these critical biological processes and for developing appropriate therapeutic approaches
to a variety of disorders, including cancer.
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CHAPTER VII
EXPERIMENTAL PROCEDURES
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Tissue culture methods - HeLa, HCT116, HCT116 p53-/- cell lines were cultured in
Dulbecco’s modified Eagles medium (DMEM)-10% fetal bovine serum (FBS) and 1%
penicillin/streptomycin antibiotic . RKO, RKO-E6 cell lines were cultured in Eagle's
minimal essential medium (EMEM)-10% FBS and 1% penicillin/streptomycin antibiotic
supplemented with 2 mM glutamine.
DNA-damaging agents - 90% confluent cultures were exposed to UV and harvested at
the indicated times. UV doses (40 J/m2) were delivered in two pulses using a stratlinker
(Stratgene). Prior to pulsing, medium was removed and replaced immediately after
treatment.
Knockdown expression of PARN or Ago-2 by siRNA - siRNAs specific for either
human PARN or Ago-2 and the control siRNA used as non-silencing were obtained from
Dharmacon RNA technologies. Cells were grown in a 10-cm plate in complete
DMEM/EMEM. At 50-60% confluence, the cells were transfected with 100 nM of
PARN, Ago-2 or control siRNA and 60 µl of Lipofectamine 2000 (Invitrogen) according
to the manufacturer’s protocol. After culturing the cells in antibiotic/FBS free medium
for 8 h, medium was changed to complete medium. After additional 16 h, cells were
transfected again and harvested for analysis 48 h after the initial transfection. To
determine the specificity of siRNAs used protein levels were monitored.
miRNA inhibitor expression plasmid transfection – Either miR-125b inhibitor
expression plasmid (HmiR-AN0096-AM03, GeneCopoeia) or control plasmid (AM03,
GeneCopoeia) were were transfected into HCT116 cells. Cells were grown in a 10-cm
plate in complete DMEM. At 50-60% confluence, the cells were transfected with 24 µg
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of either miR-152b inhibitor expression plasmid or control plasmid and 60 µl of
Lipofectamine TM 2000 (Invitrogen) according to the manufacturer’s protocol. After
culturing the cells in antibiotic/FBS free medium for 8 h, medium was changed to
complete medium. After additional 16 h (24 h after the initial transfection), cells were
harvested for analysis.
Nuclear extracts (NEs) preparation - After UV treatment, NEs were prepared from
harvested cells essentially as described (Cevher et al., 2010; Nazeer et al., 2011). Cells
were lysed by douncing in 4 ml of 10 mM Tris pH 7.9, 1.5 mM MgCl 2, 10 mM KCl, 0.5
mM dithiothreitol (DTT), and 0.5 mM phenylmethylsulfonyl fluoride (PMSF). Lysates
were centrifuged for 10 min at 6000 g, and pellets were resuspended in 20 mM Tris pH
7.9, 1.5 mM MgCl2, 25% glycerol, 0.2 mM EDTA, 0.5 mM DTT, 0.5 mM PMSF, and
0.3 M NaCl. Preparations were rocked for 30 min at 4°C and centrifuged for 30 min at
6000 g. Supernatants were quickly frozen and stored at −80°C.
Fractionation assays - The fractionation of HCT116 cells was performed using
Subcellular Protein Fractionation kit (Thermo Scientific) following the manufacturer’s
protocol. Equivalent amounts of cytoplasmic and nuclear component were subjected to
SDS-PAGE and proteins were detected by immunoblotting using antibodies against Ago2 (H-300, Santa Cruz Biotechnology), PARN (kindly provided by Dr. A. Virtanen,
Uppsala University), Topoisomerase II (H-8, Santa Cruz) and actin (A2066, SIGMA).
Immunoprecipitation assays – 100 μg of total protein from NEs prepared from different
cell lines was pre-

-A–Sepharose and immunoprecipitated

with polyclonal antibody against either PARN (H-105 Santa Cruz Biotechnology) or
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Ago-2 (Santa Cruz Biotechnology) bound to protein A-agarose beads. Antibodies were
coupled to protein A-agarose beads for 3 h at room temperature in buffer IPP (50 mM
Tris pH 7.4, 50 mM NaCl and 0.1% Nonidet P-40). Immunoprecipitations were carried
out for 3 h at 4°C in 200 μl of buffer A (1× phosphate-buffered saline (PBS): 137 mM
NaCl, 3 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, 0.01% Nonidet P-40, 0.5 mM
PMSF, and 0.04% bovine serum albumin). The beads were recovered by centrifugation
and treated at 4°C with 50 μg of RNase A/ml for 10 min. Finally, washing was performed
with buffer A plus increasing amounts of NaCl. Aliquots of pellets and supernatants were
analyzed by SDS-PAGE and immunoblotting. Results from three independent samples
were analyzed and quantified using Image J program.
Purification of recombinant proteins - A plasmid encoding the full-length Ago-2
(kindly provided by Dr. Novina, Harvard Medical School) was transformed into Rosetta
cells and GST-fusion proteins were purified by binding to and elution from glutathione–
agarose beads as described in (Wang et al., 2009). The plasmid encoding His-PARN and
its derivatives were transformed into BL21 cells, His fusion proteins were expressed and
purified by binding to and elution from Ni-Agarose column (Qiagen) as described
(Nilsson and Virtanen, 2006).
Protein-protein interaction assays - 2 μg of GST-Ago-2 or GST was incubated with
glutathione-agarose beads for 2 h at 4°C in 300 μl final volume of binding buffer (1xPBS,
0.04% bovine serum albumin, 0.5 mM PMSF, 0.001% NP40). Beads were washed
extensively six times with binding buffer. 2 μg of His-PARN derivatives (full-length, Nterminal domain (NTD) and C-terminal domain) were added to the GST-/GST-Ago-2-
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bound beads and incubated for 2 h at 4°C in 300 μl final volume of binding buffer. The
beads were washed six times with binding buffer plus 300 mM NaCl, resuspended in
loading buffer, and proteins were fractionated by 12% SDS-PAGE. Equivalent amounts
of pellets and supernatants were analyzed by immunoblotting. 2 μg His-PARN was
incubated with Ni-Magnetic beads for 2 h at 4°C in 300 μl final volume of binding buffer
(20 mM HEPES pH 7.9, 0.5 M KCl, 0.5% NP-40, 10% glycerol, 2 mM-mercaptoethanol
and 2.5 mM imidazole). Beads were washed extensively six times with binding buffer. 2
μg of GST-Ago-2 was added to the His-PARN-bound beads and incubated for 2 h at 4°C
in 300 μl final volume of binding buffer. The beads were washed six times with binding
buffer plus 400 mM NaCl, resuspended in loading buffer, and proteins were fractionated
by 9% SDS PAGE. Equivalent amounts of pellets and supernatants were analyzed by
immunoblotting
In vitro deadenylation assays - Conditions for in vitro deadenylation assays were as
described (Martinez et al., 2001). Deadenylation assays with His-PARN, derivatives of
PARN and different concentrations of GST-Ago-2 or Flag-nucleolin phospho-variants
(kindly provided by Dr. Saxena, Brooklyn College) were carried out in reaction mixtures
containing 25 mM Hepes pH 7, 100 mM NaCl, 0.1 mM EDTA, 1.5 mM MgCl2, 0.5 mM
DTT, 2.5% polyvinyl alcohol, 10% glycerol, 0.25 U RNasin, and 10 nM 7MeGpppG
capped in vitro transcribed L3(A30) RNA substrate, radioactively labeled by the inclusion
of
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P-α-UTP during in vitro transcription. Incubations were performed at 30°C for 30

min; the reactions were terminated and analyzed by electrophoresis in 10%
polyacrylamide/7 M urea gels. Results from independent samples were quantified by
using image J program.
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P-labelled p53 3’UTR substrate preparation - WT and mutant p53 3’UTRs were

amplified from luciferase constructs by PCR using a forward primer including a T3
promoter and a reverse primer with 20 adenines to create poly(A) tail at the 3’ end of the
transcript (Forward 5’-ATGGATTCAATTAACCCTCACTAAAGGGAACATTCTCCA
CTTCTTGTTCCCCACTAC-3’ and Reverse 5’-GGATGATCCATAAGCTT(A)20TGG
GATATAAAAAGGG-3’). The PCR fragments were digested with Hind III to generate
the poly(A) tail. Then polyadenylated radiolabeled RNA substrates were synthetized by
in vitro transcription with T3 polymerase as described (Cevher et al., 2010).
NEs Deadenylation assays - Conditions for NEs deadenylation assays were as described
(Cevher et al., 2010). Deadenylation assays using equivalent amounts of total proteins
from NEs from different cell lines with/without UV treatment or siRNA mediated
knockdown of Ago-2 were carried out in reaction mixtures containing 25 mM Hepes pH
7, 100 mM NaCl, 0.1 mM EDTA, 1.5 mM MgCl2, 0.5 mM DTT, 2.5% polyvinyl alcohol,
10% glycerol, 0.25 U RNasin, and 10 nM 7MeGpppG capped in vitro transcribed L3(A30)
or p53 3’UTR RNA substrate, radioactively labeled by the inclusion of 32P-α-UTP during
in vitro transcription. Protein concentrations of the NEs were equalized by Bradford
assays (Bio-Rad) before used in deadenylation reactions. Incubations were performed at
30°C for 2 h; the reactions were terminated and analyzed by electrophoresis in 10%
polyacrylamide/7 M urea gels. Results from independent samples were quantified by
using image J program.
RNA purification and microarray analysis - Nuclear RNA was purified from HeLa
cells using the RNeasy kit (Qiagen) following manufacturer’s protocol. The RNA
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concentrations of the RNA samples obtained under different conditions were equalized.
Equivalent amounts of purified RNA were used in microarray analysis. The GeneChip
Human Gene 1.0 ST (Affymetrix) expression array was used. Microarray data were
normalized using the Robust Multichip Average (RMA) method. Significant genes
determined by t-test (P < 0.05) were subsequently subjected to pathway analysis using
the Ingenuity Pathway Analysis database.
Analysis of endogenous mRNAs or miRNA abundance by qRT-PCR – Total RNA
(nuclear or total) was purified from different cell lines using the RNeasy Mini
Kit(Qiagen) according to the manufacturer’s directions. The RNA concentration of the
total RNA samples obtained under different conditions was equalized. Equivalent

random hexamer primers or oligo-d(T) primers and MMLV reverse transcriptase
(Promega) according to the manufacturer’s protocol. qPCR was performed using the
reverse transcriptase products and Taqman master mix (Applied Biosystem).
Commercially available primers (GAPDH, ACTIN, c-fos, c-myc, TP53, BCL-XL,
HDAC1 and RB1CC1) were used in the qRT-PCR reactions (Applied Biosystems).
miRNAs abundance was assessed by qRT-PCR using All-in-One™ miRNA qRT-PCR
Reagent Kits and Validated Primers (GeneCopoeia). Relative levels were calculated
using ΔCτ method.
RNA isolation and qRT-PCR analysis of mRNA half-lives - Control and PARN
knockdown RKO cells (see above) were treated with Act-D (8 µg/ml) for 30 min before
the beginning of the time course. Nuclear RNA was purified at different time points and
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analyzed by qRT-PCR. Total RNA was isolated at different time points using RNeasy
Mini Kit (QIAGEN) according to the manufacturer’s directions. p53 mRNA abundance
was assessed at each time point by qRT-PCR and normalized the non-PARN target gene
actin.
Constructs of Luciferase Reporter Vectors - Luciferase vector pEZX-MT01 with TP53
miTarget™ miRNA 3' UTR target clones (product ID: HmiT054283) was purchased
from GeneCopoeiaTM. Mutations in the miRNA targeting sites, ARE sequence or both
signals of p53 3’UTR were introduced with the QuikChange Lightning Site-Directed
Mutagenesis

Kit

(Agilent

Technologies)

and

the

following

primers

5’-

GGGTCAATTTCCGTTCGCGAATTCTGTTCTGATCTGCTTTTTCTTTGAGACTGG
G -3’ and 5’-CCCAGTCTCAAAGAAAAAGCAGATCAGAACAGAATTCGCGAACGGAAATTGACCC-3’ for ARE sequence replacement, primers 5’- CTGGATCCACCAAGACTTGTTTTATGATTTCTTTTTTCTTTTTT-3’ and 5’-AAAAAAGAAAAAAGAAATCATAAAACAAGTCTTGGTGGATCCAG-3’ for miRNA targeting
sites replacement and primers 5’-CCAAGACTTGTTTTATGCATGTCCGTTCGCGAATTCTGCTGTGATCTGCTTTTTCTTTGAGACTGG -3’ and 5’-CCAGTCTCAAAGAAAAAGCAGATCACAGCAGAATTCGCGAACGGACATGCATAAAACAAG
TCTTGG -3’ for both signals replacement following the manufacturer’s instructions.
Plasmids were sequenced to confirm the presence of the mutation. 24 µg of the different
luciferase constructs were transfected into cells using LipofectamineTM 2000 reagent
(Invitrogen).
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Luciferase assay - Cells were co-transfected with 24 µg of different luciferase constructs
(Lipofectamine TM 2000 reagent, Invitrogen) and either siRNA-targeting PARN or
control siRNA. 48 h after transfection cells were harvested and dual luciferase assay was
performed using Luc-pair miR

Luciferase kit from GeneCopoeia following

manufacturer’s instructions.
RNA immunoprecipitation (RIP) assays - Immunoprecipitation of nuclear RNAprotein complexes was performed as described (Selth et al., 2011). Briefly, cells were
treated with 1% formaldehyde, then NEs were prepared followed by sonication. Extracts
were treated with DNase (TURBO DNA-free Kit, Ambion), and the resulting material
was immunoprecipitated with antibodies against PARN (H-105) or control rabbit IgG
(Sigma). Protein-RNA complexes were treated with proteinase K and reversal of crosslinking. RNA was extracted from the IPs with phenol-chloroform and analyzed by RTqPCR assays.
RT-qPCR Assays - As described before (Cevher et al., 2010; Nazeer et al., 2011),
equivalent amounts (2 μg) of purified RNA were used as a template to synthesize cDNA
using random hexamer primers, oligo-d(T) primers, and GoScript Reverse Transcriptase
(Promega). Relative levels were calculated using the ΔCτ method.
RNA Pull-down - Biotin-labeled RNAs were in vitro transcribed with the biotin RNA
labeling mix (Roche) and T7 RNA polymerase (Promega) following manufacturer’s
instructions. 3 µg of biotinylated RNA treated with RNase free DNase I (Promega) was
heated to 9 0C in RNA structure buffer (10 mM Tris pH7, 0.1 M KCl, 10 mM MgCl2) and
shifted to room temperature for 20 min for proper folding. Folded RNA was then mixed
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with 1 mg of NEs in RIP buffer (150 mM KCl, 25 mM Tris pH 7.4, 0.5 mM DTT, 0.5%
NP40, 1 mM PMSF and protease inhibitor) and incubated at room temperature for 1 h. 60
µl of washed Streptavidin magnetic beads were added to each reaction and incubated at
room temperature for another 1 h. Beads were washed 3 times with RIP buffer and eluted
in SDS buffer and analyzed by immunoblotting.
RACE-poly(A) test (PAT) assays - Nuclear RNA from RKO cells treated with
PARN/control siRNA for 48 h (see above) was isolated using Rneasy Mini Kit
(QIAGEN) according to the manufacturer’s directions. 100 ng of RNA was reversetranscribed using oligo (dT)-anchor primer (5’- GGGGATCCGCGGTTTTTTTTTT -3’)
and GoScript Reverse Transcriptase (Promega). 1 µl of each cDNA was used for PCR
amplification by GoTaq PCR mix (Promega) using p53 3’UTR specific primer (5’CTGCATTTTCAC-CCCACCCTTCC -3’ located 90 bp upstream of poly(A) site) and
oligo(dT)-anchor. PCR products were separated in 8% PAGE and the gels were stained
with 0.2 mg/ml Ethidium Bromide for 20 min as previously described (Kleiman et al.,
1998).
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